 
Version 3.0  1 
7/11/2017  
 
A Retrospective/Prospective Study to Assess Safety, Toler ability, and Efficacy of 
Sofosbuvir based Direct Acting Antivira l (DAA) Therapy for Hepatitis C Treatment 
in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant   
PROTOCOL  
VERSION  3.0 July  11, 2017 
Study Sponsor(s):   The  National  Institute  of Allergy and  Infectious  Diseases  
(NIAID)    
NIAID Funding  Mechanism:   U01 
Clinical Trial Phase:    Phase IV (non‐IND) 
Study Drug Provider :   Gilead Sciences  
NCT Number:        [STUDY_ID_REMOVED]  
  
  
 
Version 3.0  2 
7/11/2017  
Version of Protocol – DAIDS-ES 12044 (STOP-CO) 
A Retrospective/Prospective Study to Assess Safety, Toler ability, and Efficacy of 
Sofosbuvir based Direct Acting Antivira l (DAA) Therapy for Hepatitis C Treatment 
in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant   
VERSION  3.0 July  11, 2017 
Study Sponsor(s):   The  National  Institute  of Allergy and  Infectious  Diseases  
(NIAID)    
NIAID Funding  Mechanism:   U01 
Clinical Trial Phase:    Phase IV (non‐IND) 
Study Drug Provider :   Gilead Sciences  
 
EXTRAMURAL  PRIN.  INVESTIGATOR  
PETER  STOCK, MD, PHD 
University  of California,  San Francisco  
505 Parnassus  Ave.M‐884 
San Francisco,  CA 94143‐0780 
Phone:  415‐353‐8617 
Fax: 415‐353‐ 8974 
E‐mail: Peter.Stock@ucsf.edu  NIH INTRAMURAL  PRIN.  INVESTIGATOR  
HENRY MASUR, MD, 
NIH/CC/CCMD  
10 Center Drive, Room 2C145 
Bethesda,  MD 20892, USA  
Phone:  301‐496‐9320 
Fax: 301‐402‐ 1213 
E‐mail: HMasur@cc.nih.gov  ASSOCIATE  INVESTIGATORS  
SHYAM KOTTILIL , MD (UMD) 
SARAH KATTAKUZHY , MD (UMD) 
NORAH TERRAULT , MD (UCSF) 
MARION PETERS , MD (UCSF) 
ELEANOR WILSON , MD (UMD) 
ELANA ROSENTHAL , MD (UMD) 
JOSEPH KOVACS , MD (NIH CC) 
 
MEDICAL  MONITOR,  NIAID 
BEVERLY ALSTON SMITH, MD 
NIAID/DAIDS  
5601 Fishers Ln 
BG 5601FL, RM 9F50 
Rockville,  MD 20852, USA 
Phone:  301‐ 435‐3773  
Fax: 301‐480‐ 4522 
E‐mail: Beverly.alston@nih.gov  
 REGULATORY  CONTACT  
MARY K. HALL C.I.P 
Critical  Care Medicine  Dept. 
National Institutes  of Health 
10 Center Drive, Bldg  10/2C145  
Bethesda,  MD 20892‐1476 
Phone:  301‐496‐9320 
Fax: 301‐402‐ 1213 
Email : mkhall@cc.nih.gov  
 PROTOCOL  PHARMACIST  
SCOTT FIELDS 
UCSF INPATIENT  PHARMACY 
ATTN: INVESTIGATIONAL  DRUGS 
505 Parnassus  Ave.,  Room M39C 
San Francisco,  CA 94143 
Phone : 415‐ 353‐1798  
Email : scott.Fields@ucsf.edu  
BIOSTATISTICIAN  
MICHAEL PROSCHAN , BRB/NIAID  
NIAID 
5601 Fishers Ln 
BG 5601FL  RM 4C30 
Rockville,  MD 20852 
Phone:  240‐669‐5245 
Fax: 301‐480‐ 0912 
Email: michael.proschan@nih.gov  PROJECT  MANAGER,  UCSF 
RODNEY  ROGERS 
University  of California,  San Francisco  
505 Parnassus  Ave. M‐884 
San Francisco,  CA 94143‐0780 
Phone:  415‐514‐6454 
Fax: 415‐353‐ 2233 
E‐mail: Rodney.Rogers@ucsf.edu  
 
  

 
Version 3.0  2 
7/11/2017  
Collaborating  Investigators:     Brad Wood MD,  DMRD,  CC, NIH 
     David  E. Kleiner MD,  DCS,  NCI, NIH 
Theo Heller  MD,  LDB, NIDDK, NIH 
     Robert  Redfield,  MD,  University  of Maryland  
     Coleman  Smith, MD,, Medstar Georgetown  Transplant  Inst. 
     Mark  Sulkowski,  MD,  Johns  Hopkins 
     Christine  Durand, MD,  Johns  Hopkins 
     Shirish  Huprikar,  MD,  Mt. Sinai Medical Center 
Sander Florman, MD,  Mt. Sinai Medical Center 
     Lorna  Dove, MD,  Columbia  University  
     Jean  Emond,  MD,  Columbia  University  
     Emily  Blumberg,  MD,  University  of P ennsylvania  
Kim Olthoff, MD,  University  of Pennsylvania   
  
    
Roles  and responsibilities  of study team at NIH (CCMD/NIAID)  on this U01 Project 
 
Henry Masur, MD is the NIH Intramural  Principal Investigator  and will oversee  the protocol and all the 
individuals  working on it at The NIH Clinical Center.  Th ese individuals  will be listed  on the NIH Protocol 
Application  as Associate  Investigators;  and may include federal  employees,  special  volunteers,  and/or 
contractors.  Dr. Masur will be authorized  to obtain informed  consent,  have access to identifiable  data, 
and participate  in data analysis and manuscript  preparation/review.  
The Lead Associate  Investigator  at NIH will directly oversee  the protocol subjects  admitted to the 
clinical center  for pharmacokinetic  and viral  kinetic monitoring,  as well as participate  in monitoring  of 
patient  safety,  take routine calls regarding  safety and event reporting  with  the extramural  
investigators,  obtain informed  consent, have access to identifiable  data and participate  in data analysis 
and manuscript  preparation/review.   
Associate  Investigators  at the NIH will see protocol subjects during  outpatient  and inpatient visits, participate  in 
monitoring  for patient safety, take routine  calls from subjects, obtain informed  consent, have access to 
identifiable  data and participate  in data analysis and manuscript  preparation/review.  
The study coordinator/nurse  will also be authorized  to obtain informed  consent,  have access to 
identifiable  data and may participate  in manuscript  preparation/review.  
Mary Hall will provide regulatory  support for the NIH site. She will not obtain informed  consent  but 
may have access to identifiable  data. 
Michael Proschan,  PhD is the NIAID  biostatistician  who wrote the statistical  section  of the protocol.  He 
will have access to identifiable  data and participate  in data analysis and manuscript  
preparation/review.   
  
 
Version 3.0  3 
7/11/2017 PROTOCOL SIGNATURE PAGE 
 
Protocol: 
 STOP-CO Version/Date:  Version 3.0/July 11, 2017 
Title:   A Retrospective/Prospective Study to Assess Safet y, Tolerability, and Efficacy of Sofosbuvir based 
Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre 
or Post Liver Transplant    
 I will conduct the study in accordance with the provisions of this protoc ol and all applicable protocol-
related documents. I agree to conduc t this study in compliance with United States (US) Health and 
Human Service regulations (45 CF R 46); applicable U.S. Food and Drug Administration regulations; 
standards of the International Conference on Harmonization Guideline fo r Good Clinical Practice (E6); 
Institutional Review Board/Ethics Committee determinations; all applicable in-count ry, state, and local 
laws and regulations; and other applicable requireme nts (e.g., US National Institutes of Health, Division 
of AIDS) and institutional policies.       
___________________________________  
Site Principal Investigator Name (Print)  
     
 
____________________________________                                    _________________  
Site Principal Investigator (Signature)                                        Date  
    
 
 
 
   
 
Version 3.0  4 
7/11/2017 TABLE OF CONTENTS 
 
TABLE OF CONTENTS .............................................................................................................  4 
PROTOCOL SUMMARY ........................................................................................................... 8  
PRÉCIS ........................................................................................................................ ................ 10  
1.0 INTRODUCTION........................................................................................................... 11 
1.1  RATIONALE  FOR  THE  STUDY ............................................................................................. 12  
2.0 OBJECTIVES ................................................................................................................. 16  
2.1  PRIMARY OBJECTIVES  ............................................................................................................... 16  
2.2  SECONDARY OBJECTIVES  .......................................................................................................... 17  
3.0 STUDY DESCRIPTION ................................................................................................ 17  
3.1  RETROSPECTIVE ARM ............................................................................................................... 18  
3.2  PROSPECTIVE ARM .................................................................................................................... 18  
3.3  STUDY  ENDPOINTS .............................................................................................................. 19  
3.3.1  Primary En dpoints  ......................................................................................................................... 19  
3.3.2  Secondary En dpoints ........................................................................................................... ........... 19 
4 STATISTICAL ANALYSIS .............................................................................................. 19  
4.1  SAMPLE SIZE REQUIREMENTS  ................................................................................................... 19  
4.1.1  Primary Endpoint .............................................................................................................. ............. 20  
4.1.2  Secondary En dpoints ........................................................................................................... ........... 20 
4.1.3  Safety Endp oints .............................................................................................................. ............... 20  
4.1.4  Other Endpoints of Interest ................................................................................................... ......... 20 
4.2  ANALYSIS POPULATIONS  .......................................................................................................... 20  
4.2.1  Efficacy P opulatio n ........................................................................................................... ............. 20  
4.2.2  Safety Popul ation ............................................................................................................. .............. 20  
4.3  DATA HANDLING CONVENTIONS  .............................................................................................. 21  
4.4  EFFICACY ANALYSES  ................................................................................................................ 21  
4.4.1  Primary Analysis .............................................................................................................. .............. 21  
4.4.2  Secondary An alysis  ........................................................................................................................ 22  
4.5  SAFETY ANALYSIS  .................................................................................................................... 22  
5 PATIENT POPULATIONS ............................................................................................... 22  
5.1  RETROSPECTIVE ARM INCLUSION CRITERIA  ............................................................................ 22  
5.2  PROSPECTIVE ARM INCLUSION /EXCLUSION CRITERIA  ............................................................. 23  
6 SCHEDULE OF VISITS AND PROCEDURES: RETROSPECTIVE ARM............... 25  
6.1  WAIVER OF CONSENT ................................................................................................................ 25  
6.2  CONSENT FOR LIVER STAGING AND LONG TERM FOLLOW -UP ................................................... 25  
6.3  TIME-POINTS  ............................................................................................................................. 25 
7 SCHEDULE OF VISITS AND PROCEDURES: PROSPECTIVE ARM .................... 25  
7.1  SCREENING (VISIT 1) ................................................................................................................. 25  
7.2  LIVER STAGING (SCREENING ) ................................................................................................... 26  
7.3  PHYSICAL EXAMINATION , INCLUDING VITALS SIGNS  ............................................................... 26  
7.4  STARTING SOF/LDV  (VISIT 2) ................................................................................................. 26  
 
Version 3.0  5 
7/11/2017 7.5  ADVERSE EVENT ASSESSMENT AND CONCOMITANT MEDICATIONS  .......................................... 26  
7.6  STUDY VISITS DURING TREATMENT  .......................................................................................... 26  
7.7  WEEK 12 OR 24 VISIT / END OF TREATMENT VISIT .................................................................. 27  
7.7.1  Liver Staging (End of Treatment): ............................................................................................. .... 27 
7.8  DAY OF TRANSPLANT (FOR PRE-TRANSPLANT SUBJECTS ): LIVER EXPLANT TISSUE  ............... 27  
7.9  POST TREATMENT FOLLOW UP VISITS  ....................................................................................... 27  
7.10 EARLY TERMINATION AND EARLY TREATMENT DISCONTINUATION  ....................................... 27  
8 STUDY AGENT/INTERVENTIONS: PROSPECTIVE ARM ...................................... 27  
8.1  DISPOSITION AND DISPENSATION  ............................................................................................. 27  
8.2  PACKAGING AND LABELING OF STUDY DRUGS  ........................................................................ 28  
8.3  FORMULATION OF FDC  SOF/LDV ............................................................................................ 28  
8.4  STORAGE AND HANDLING OF FDC  SOF/LDV ........................................................... 28  
8.5  DOSAGE AND ADMINISTRATION OF FDC  SOF/LDV ................................................................ 28  
8.6  TREATMENT OF PARTICIPANTS  ................................................................................................. 28  
8.7  DOSE MODIFICATIONS /TOXICITIES  ........................................................................................... 29  
8.8  DOSE MODIFICATION FOR SOF/LDV ........................................................................................ 29  
8.9  CRITERIA REQUIRING DISCONTINUATION OF SOF/LDV .......................................................... 29  
8.9.1 Treatment Failure Criteria After Stopping SOF/LDV  ................................................................. 30  
8.10 HIV  VIROLOGIC REBOUND CRITERIA FOR SUBJECTS ON ARV S .............................................. 30  
8.11 CONCOMITANT MEDICATIONS  .................................................................................................. 30  
9 EVALUATION OF SAFETY ............................................................................................ 32  
9.1  FOLLOW -UP OF ABNORMAL LABORATORY TEST VALUES  ....................................................... 32  
9.2  CRITERIA FOR PREMATURE WITHDRAWAL AND STOPPING RULES  .......................................... 32  
10 ADVERSE EVENT REPORTING AND MONITORING ............................................. 32  
10.1 DEFINITIONS  ..............................................................................................................................  32 
10.2 ASSESSING ADVERSE EVENTS ................................................................................................... 34  
10.3 SEVERITY GRADING  .................................................................................................................. 34  
10.4 CAUSALITY ASSESSMENT  ......................................................................................................... 35  
10.5 REPORTING PROCEDURES : PROSPECTIVE ARM ......................................................................... 35  
10.5.1  Adverse E vents ................................................................................................................ ............... 35  
10.5.2  Serious Adverse  Events ........................................................................................................ .......... 36 
10.5.3  AE and SAE Recording/Docu mentation/Follow-up ....................................................................... 36  
10.5.4  Adverse Events and Serious Adverse Events Exempt from Reporting ............................................ 36  
10.6 REPORTING PROCEDURES : RETROSPECTIVE ARM .................................................................... 36  
11 SCHEDULE OF EVENTS ................................................................................................. 37  
11.1 SCHEDULE OF EVENTS PROSPECTIVE ARM ............................................................................... 37  
11.2 SCHEDULE OF EVENTS RETROSPECTIVE ARM (WAIVER OF CONSENT ) .................................... 39  
11.3 SCHEDULE OF EVENTS RETROSPECTIVE ARM: ONE PROSPECTIVE VISIT ................................. 39  
12 MECHANISTIC STUDIES: PROSPECTIVE ARM ...................................................... 40  
13 HAZARDS/DISCOMFORTS/RISKS: PROSPECTIVE ARM ...................................... 41  
13.1 DRUGS  .............................................................................................................................. ......... 41 
13.2 PROCEDURES  ............................................................................................................................. 41 
13.2.1  Phlebotomy .................................................................................................................... ................. 41  
14 HUMAN SUBJECT PROTECTIONS .............................................................................. 42  
14.1 GENDER , ETHNICITY , AND RACE CONSIDERATIONS  ................................................................. 42  
 
Version 3.0  6 
7/11/2017 14.2 CHILDREN AND PREGNANT WOMEN  ......................................................................................... 42  
14.3 HIV  TESTING  ............................................................................................................................. 42 
15 BENEFITS/COMPENSATION/ALTERNATIVES ........................................................ 42  
15.1 BENEFITS  .............................................................................................................................. ..... 42 
15.2 ALTERNATIVES  .......................................................................................................................... 42  
16 DATA SAFETY AND MONITORING ............................................................................ 42  
16.1 SPECIFIC CRITERIA TO PAUSE ENROLLMENT FOR VIROLOGIC /THERAPEUTIC FAILURE AND FOR 
RESISTANCE  .............................................................................................................................. ............. 43  
16.1.1  Virologic/Therapeutic Failure Cr iteria to Pause Enrollment ........................................................ 43  
16.2 IF CRITERIA TO PAUSE ENROLLMENT ARE MET ....................................................................... 43  
17 STUDY SITE MONITORING .......................................................................................... 43  
18 STORED SAMPLES AND FUTURE RESEARCH: PROSPECTIVE ARM............... 44  
18.1 RESEARCH USE OF STORED HUMAN SPECIMENS AND DATA .................................................... 44  
19 DATA MANAGEMENT PLAN ........................................................................................ 45  
20 STUDY RECORDS RETENTION ................................................................................... 45  
21 ANONYMITY AND CONFIDENTIALITY .................................................................... 46  
22 PROTOCOL REGISTRATION........................................................................................ 46 
23 CONSENT PROCEDURES ............................................................................................... 47  
REFERENCES .................................................................................................................... ........ 47 
 
 
         
 
Version 3.0  7 
7/11/2017 ABBREVIATIONS   
AA African America n 
AE Adverse Events 
ALT alanine aminotransferase 
ANC absolute neutrophil count 
AUC Area under the curve 
BMI Bod y mass index 
CHC Chronic hepatitis C 
DAA Direct actin g antiviral 
ECG Electrocardio gram 
ESA Er ythropoiesis stimulatin g agent 
ETR end of treatment response: <LLOQ HCV RNA at the end of treatment 
EVR earl y virolo gic response: <LLOQ HCV RNA or 2-lo g decline at Week 12 (partial EVR) 
FDA Food and Dru g Administratio n 
FDC Fixed dose combinatio n 
G-CSF granuloc yte colon y stimulatin g facto r 
GT-1, -2, and -3 Genot ype 1, 2, and 3 
HBV hepatitis B virus 
HCV hepatitis C virus 
Hgb hemo globin 
HIV human immunodeficienc y virus 
IL28B Interleukin 28B 
IFN interfero n 
IRB Institutional Review Boar d 
ISG interferon-stimulated gene 
LDV Ledipasvi r 
LI Lead investi gator 
LOD Level of detectio n 
LLOQ Lower Level of quantificatio n 
MELD Model for En d-Stage Liver Disease 
NIAID National Institute of Aller gy and Infectious Diseases 
NIH National Institutes of Health 
PBMC peripheral blood mononuclear cell 
pegIFN Pe gylated Interfero n 
PI principal investi gator 
sofosbuvi r sofosbuvi r 
QWBA quantitative whole- body autoradio graphy  
RBV  ribaviri n 
RVR Rapid virolo gic response; <LLOQ HCV RNA at Week 4 
SAE Serious adverse events 
SOC Standard of care  
SOF Sofosbuvi r 
SVR sustained virologic response <LLOQ HCV RNA at 24 weeks (or 6 months) after the end 
of treatment 
TVR Telaprevi r 
 
Version 3.0  8 
7/11/2017 PROTOCOL SUMMARY 
 Full Title : A Retrospective/Prospective Cohort St udy to Assess Safety, Tolerability, 
and Efficacy of Sofosbuvir based Di rect Acting Antiviral (DAA) therapy 
for Hepatitis C Treatment in HIV/HC V Coinfected Subjects Pre or Post 
Liver Transplant   
Short Title: Sofosbuvir based DAA therapy in HIV/ HCV coinfected pre or post liver 
transplant  
Study Name:   S T O P - C O  
DAIDS ES #: 12044 
Clinical Phase:  Phase IV 
Sample Size: 10+ prospective (up to 20) 40+ retrospective  
Accrual Period: 12 months  
 Study Population: HIV+ Adults with decompensated liver disease pre or post liver transplant 
with chronic hepatitis C virus (HCV) infection 
 Participating Sites: Enrolling Centers: University of California, San Francisco, Mt. Sinai 
Medical Center, Columbia Universit y, and University of Pennsylvania, 
University of Maryland, Georgeto wn University, Johns Hopkins 
University; Collaborating Center: NIH Clinical Center.  
 Study Design:  Retrospective/Prospective, open- label study using sofosbuvir based DAA 
therapy to treat HIV/HCV coinfect ed pre or post liver transplant 
participants   
Primary Objectives: 1. To assess the safety, tolerability, and efficacy of sofosbuvir based DAA therapy for 12 - 24 weeks in HIV/HCV coinfected participants pre- and 
post-liver transplant. 
 
2.  To assess the safety, tolerability, and efficacy of a fixed dose combination (FDC) of sofosbuvir an d ledipasvir (SOF/LDV) for 12 - 24 
weeks in HIV/HCV coinfected participants pre- and post-liver transplant 
  
Secondary Objectives: 
1. To evaluate changes in HCV vi ral kinetics with fixed dose combination (FDC) SOF/LDV or 
sofosbuvir based DAA therapies in HIV/HCV co infected subjects with pre or post liver 
transplant HCV  
2. To evaluate the proportion of subjects with HCV viral loads below the level of quantification at 
various time point s of the study 
 
3. To determine sustained virologic response ra tes with FDC SOF/LDV or sofosbuvir based DAA 
therapies.   
 
Version 3.0  9 
7/11/2017  
4. To identify the determinants of response to in terferon sparing therapy in eradicating HCV in pre 
or post liver transplant HI V/HCV coinfected subjects  
 
5. To identify the host genetic, protein, gene, and proteomic factors that are associated with 
responses to interferon (IFN) sparing therapy in pre or post liv er transplant HIV/HCV coinfected 
subjects ( prospective arm only ) 
 
6. To determine if levels of interferon-stimulate d genes (ISG) expression in PBMCs or liver can 
predict rapid virologic response (RVR), end trea tment response (ETR), and sustained virologic 
response (SVR) in subjects re ceiving IFN sparing therapy ( prospective arm only ) 
 
7. To evaluate the proportion of subjects whos e ALT normalizes during therapy and between 
baseline and SVR  
8. To evaluate the emergence of viral resistance during therapy with FDC SOF/LDV or sofosbuvir 
based DAA therapies.   
9. To evaluate change in liver fi brosis and liver function before  and after treatment with FDC 
SOF/LDV or sofosbuvir  based DAA therapies. 
 
Version 3.0  10 
7/11/2017 PRÉCIS 
 Liver transplantation (LT) in HIV/HCV patients results in worse outco mes than in HCV or HIV patients 
[1-4]. Similarly, survival rates af ter LT are significantly lower in HIV/HCV patients than HCV patients 
[1, 2, 5, 6]. While 1- year and 3- year survival rates in HCV monoi nfection are reported at 76-92% and 
72-79%, rates with HIV and HCV coinfection are reported at 67-88% and 56-62%. Spontaneous HCV 
clearance after LT is rare and reinfection with hepatitis C after liver transplantation is nearly universal. Post-transplant hepatitis C is a common problem in the management and survival of HIV/HCV 
coinfected patients after liver tran splantation. HCV treatment is often initiated after LT to remove the 
viral antagonist prior to  further disease progression or decomp ensation. Rates of sustained virologic 
response to treatment with interfe ron (IFN) and ribavirin (RBV) afte r liver transplantation are low 
(around 14.8%). Moreover, overlapping toxiciti es between antiretrovirals (ARVs) and 
interferon/ribavirin can cause toxic ities in coinfected patients that require treatment cessation, ultimately 
leading to fewer patients who ar e able to complete treatment.  
 Recently, several trials have conf irmed the efficacy of potent dire ct acting antiviral (DAA) therapy 
without concomitant IFN in the tr eatment of HCV.  One such drug has been sofosbuvir, an NS5B 
inhibitor which in combination with  IFN-based or IFN free regimens in  several trials [7-9] has been 
highly effective. In HCV infected pre transplant subjects,  the use of sofosbuvir and ribavirin treatment 
prior to transplantation prevented HCV recurren ce in the majority of subjects who had HCV RNA 
suppressed for at least 4 weeks prio r to transplant [10]. In subjects who developed recurrent hepatitis C 
post-transplant, the use of sofosbuv ir and ribavirin showed promising early results with over 70% of 
subjects achieving early sustained virologic response (SVR) [11]. More  recently, the use of fixed dose 
combination (FDC) sofosbuvir-ledipasvir with or wit hout ribavirin has been shown to be effective in 
HCV monoinfected subjects in cluding cirrhotics with SVR rates of  at least 95%. [ 12, 13] [14, 15] Drug 
interaction studies have been completed with several HIV antiretrovirals and treatment trials of SOF/LDV in HIV/HCV coinfected subjects have been initiated. Hence, an idea l regimen to treat this 
difficult patient population will be an interferon- free, directly acting antiviral treatment.  
   
 
Version 3.0  11 
7/11/2017 1.0 INTRODUCTION 
Chronic hepatitis C virus infecti on is a major public health prob lem with an estimated 180 million 
people infected worldwide [1]. In the United States an estimated 4.1 million people are infected and is 
the principal cause of death from liver disease and l eading indication fo r liver transplantation in the U.S 
[16-18]. Significant advances have been made with  the advent of directly  acting antivirals (DAA) 
against HCV over the last few years.   Liver transplantation for hepatitis C and HIV coinfection has become a controversial indi cation for liver 
transplantation because of recently reported poor out comes.  At the same tim e, the demand for liver 
transplantation in this ch allenging cohort of patients  has been increasing, as the incidence of HCV has 
been reported to be between 23-33% in HIV infected  people. Natural history st udies have demonstrated 
accelerated rates of hepatic fibrosis as well as complications of cirrhosis as compared to HCV 
monoinfected people.  As a result, liver disease has now  become a leading cause of death in HIV-
infected subjects.     Survival rates following liver transplantation in HBV/HIV coinfected recipients are excellent and 
comparable to HBV monoinfected reci pients. This is the proof that liver transplantation in the HIV 
infected recipient is safe a nd effective providing the coinfection can be controlled in the 
immunosuppressed HIV-infected recipi ent.  Unfortunately, the 1-year and 3-year survival rates are 
reported at 76-92% and 72-79% in the HCV monoinfe cted recipients, compared  to 67-88% and 56-62% 
in HCV/HIV coinfected recipients . The poorer results in the coinfe cted recipients are related to 
accelerated recurrence of HCV, and higher incidence of multisystem or gan failure in the presence of 
recurrent HCV. Furthermore, the accelerated pa ce of HCV recurrence has been exacerbated by a 
surprisingly high incidence of rejection in the HIV/HCV coinfected recipients , and the requirement for 
additional immunosuppression to reve rse the rejection.  Therapy to treat HCV with interferon and 
ribavirin both pre- and post-transpl ant has yielded dismal results, with  sustained virol ogic response less 
than 15%. The overall success in e liminating HCV are poor in HCV m onoinfected recipients, but even 
worse in the HCV/HIV coinfected recipient as a result of overlapping toxici ties between ARVs and 
interferon causing toxicities that require treatment cessation. The use of  interferon-based regimens in the 
post-transplant period is further pr oblematic based on the surprising hi gh rejection rates observed in the 
HIV infected recipients. Furthermore,  use of RBV in HIV/HCV coinfected subjects is associated with an 
increased incidence of anemia that requires dose reductions, in terruptions and treatment with 
erythropoietin. All thes e increase the cost and adverse event prof ile of the therapeutic regimen, which is 
heightened in pre and post, transplant HIV-infected r ecipients.  Since liver transplantation uses a scarce 
resource, and results are closely monitored by regulatory agencies, ma ny centers have stopped 
performing this procedure. Sadly, the cessation of transplanting HIV/HCV coinfected recipients is occurring just as potent DAA thera py is dramatically improving the sa fety and efficacy of anti-HCV 
therapy. The ability to safely trea t HCV with interferon-free, ribavi rin free directly acting antiviral 
agents with low-potential for drug interactions will be a major clin
 ical feat that will lead to a reduction 
in the need for liver transplants,  improved graft survival and improve d overall morbidity and mortality 
in this challenging patient population.  
 Recently, several trials have conf irmed the efficacy of potent DAA therapy without  concomitant IFN in 
the treatment of HCV.  One such drug has been sofosbuvir, an NS5B inhib itor which in combination 
with IFN-based or IFN free regimens in several tria ls [7-9] has been to be highly effective. In HCV 
infected pre transplant subjects, the use of sofosb uvir and ribavirin treatment prior to transplantation 
 
Version 3.0  12 
7/11/2017 prevented HCV recurrence in the ma jority of patients who were HCV RNA suppressed at transplant 
[10]. In subjects who developed recurrent hepatitis C post-transplant, the use of sofosbuvir and ribavirin 
showed promising early results w ith over 70% of subjects achieving early sustained virologic response 
(SVR) [11]. More recently, the use of FDC SOF/LDV w ith or without ribavirin has been shown to be 
effective in HCV monoinfected subjects including cirrh otics with SVR rates of at least 95% [12, 13] [14, 
15]. The ongoing NIAID SYNERGY trial of the FDC SOF/LDV has shown SVR4 rates of 100% in 
HCV-monoinfected subjects includin g cirrhotics [19]. Drug interacti on studies have been completed 
with several HIV antiretrovirals and treatment trials  of SOF/LDV in HIV/HCV coinfected subjects have 
been initiated. The firs t of such is the ongoing NIAID ERADIC ATE study using the FDC of SOF/LDV  
in HIV/HCV coinfected subjects on or off antire trovirals. In this study, viral suppression occurred 
rapidly, no major toxicities or HI V breakthroughs were observed and treatment was safe and well 
tolerated. 
1.1 RATIONALE FOR THE STUDY 
 
In the United States 4.1 million pe ople are infected with  hepatitis C virus (H CV) and 1.1 million people 
are infected with human immunodeficie ncy virus (HIV)[16]. It is estima ted that about one third of HIV-
infected individuals are also infect ed with hepatitis C, likely due to shared risk factors for transmission 
[20-23]. While morbidity and mortal ity resulting from HIV infection has dramatically decreased over 
the past three decades due to the advent of antir etroviral (ARV) therapy, de aths related to HCV are 
substantial [24, 25]. HCV treatment in HIV/HCV coinfected individuals is associated with decreased rates of virologic response and is further complicated by dr ug interactions and hi gh rates of toxicities 
[26, 27].  In the United States and We stern world, hepatitis C is the pr incipal cause of death from liver 
disease and the leading indication for liver transpla ntation and, currently, HCV- associated deaths are 
comparable to HIV-associated deaths [22]. Coinfec tion leads to accelerated progression of fibrosis and 
cirrhosis [28-31], increased risk of developing decompensated liver disease and increased risk for 
hepatocellular carcinoma (see table) [30, 32-34].  
 Liver transplantation (LT) is the only viable option for patients with  advanced HCV-induced cirrhosis 
and liver failure. Although historically HIV was considered a contraindication for liver transplantation, 
studies have shown good transplant ation outcomes and minimal HIV-related complications in ARV 
treated patients [35]. Neve rtheless, HIV infected patients are not  only less likely to receive a LT than 
non-infected patients, but they are also at a higher risk of death during the waiting period prior to LT 
[36].  Liver transplantation in HIV/HCV patients results in  worse outcomes than in HCV or HIV patients [1-
4]. Similarly, survival rates after LT are significan tly lower in HIV/HCV patients than HCV patients [1, 
2, 5, 6]. While 1- year and 3- year survival rate s in HCV monoinfection are reported at 76-92% and 72-
79%, rates with HIV and HCV coin fection are reported at 67-88% and 56-62% [1, 6, 35, 37] Recent 
studies have shown increased levels of graft loss and acute rejection [6, 35] in coinfected subjects. 
Spontaneous HCV clearance after LT is rare [35]  and reinfection with hepatitis C after liver 
transplantation is nearly universal . Recurrence of HCV disease is ofte n more severe in subjects with 
coexistent HIV infection [1, 37] Seve ral studies have demonstrated that  progression of fibrosis in post 
LT is significantly faster than the expected natural history of the disease in the normal host [35, 37, 38]. 
Resultantly, HIV/HCV patient
s have mo re fibrosing cholestatic hepatitis,  fibrosis, cirrhosis, severe graft 
fibrosis and acute HCV events than  HCV monoinfected patients. HCV r ecurrence is the leading cause of 
 
Version 3.0  13 
7/11/2017 death in both groups, but is more  frequent in the HIV/HCV group. In this regard, post-transplant 
hepatitis C is a common problem in the management and survival of HIV/HCV coinfected patients after 
liver transplantation. [6, 35] 
 
A second transplantation is not a realistic option for mo st patients, thus, HCV treat ment is often initiated 
after LT to remove the viral anta gonist prior to further disease progression or decompensation. In 
coinfected subjects, the durations of treatment and dos es used were lower than in monoinfected subjects, 
mainly because of drug-drug interact ions with the ARVs that subjects are receiving for the treatment of 
HIV [37] Rates of sustained virol ogic response to treatment with in terferon (IFN) and ribavirin (RBV) 
after liver transplantatio n are similar in both groups (All 4), albeit very low (around 14.8%) However, 
overlapping toxicities between ARVs and interferon can cause toxicities  in coinfected subjects that 
require treatment cessation, ultimately  leading to fewer subjects who are able to complete treatment 
[37]. Graft rejection associated with the use of pr o-inflammatory cytokines such as interferon alpha 
makes post-transplant treatment of hepatitis C less desira ble in this patient popul ation Hence, an ideal 
regimen to treat this patient populat ion will be an interferon-free, di rectly acting antiviral treatment. 
Several studies have now demonstrated the effi cacy of SOF/LDV in subjects with cirrhosis and 
SOF/RBV in transplant subjects  [10-13].  SOF/LDV (HARVONI) is now approved in the US for the 
treatment of chronic hepatitis C (C HC) genotype 1 infection in adults. Safety and efficacy of SOF/LDV 
have not been established in subjects with deco mpensated cirrhosis. Hence, we propose to perform a 
pilot study using SOF/LDV fixed dose combination fo r 12 - 24 weeks to treat HIV/HCV coinfected 
subjects who are awaiting liver transp lant or have received a liver tr ansplantation and present with post-
transplant hepatitis C. This study will provide a proof of concept to er adicate chronic hepatitis C in this 
vulnerable population and alter the natural history of post- transplant hepatitis C.  
 
Sofosbuvir: sofosbuvir (formerly PSI-7977) is a nucleotid e analog that is a potent and selective 
inhibitor of NS5B-directed hepat itis C virus (HCV) replicon RNA rep lication in vitro approved for the 
treatment of chronic HCV infection.  Please refer to the package inse rt for additional information on sofosbuvir including [39]: 
 In Vitro Anti-HCV Activity Nonclinical Pharmacokinetics and In Vitro Metabolism Nonclinical Pharmaco logy and Toxicology 
Clinical Experience Clinical Experience with sofosbuvir Activity of sofosbuvir against Human Immunodeficiency Virus  
Overall sofosbuvir SAE Summary  Ledipasvir (formerly GS-5885) : ledipasvir is a novel HCV NS5A inhibitor that has demonstrated 
potent anti-HCV activity against genotype (1a a nd 1b) HCV infection.  
 Please refer to the package insert for additi onal information on le dipasvir including: 
 In Vitro Anti-HCV Activity Nonclinical Pharmacokinetics and In Vitro Metabolism Nonclinical Pharmaco logy and Toxicology 
 
Version 3.0  14 
7/11/2017 Clinical Experience  
Summary of Additional Clinical Experience with ledipasvir 
The adult safety database for ledipasvir incl udes data for over 500 healthy volunteers and over 
1,000 subjects exposed to at least one dose of le dipasvir in the 6 ongoing Phase 2 studies. Over 
700 subjects have been exposed to 12 weeks of ledipasvir  containing regimens. 
 Safety Summary: In summary, the sa fety and PK data support ongoing eval uation of ledipasvir in 2 or 3 
drug combination regimens. An unblinded Da ta Monitoring Committee (DMC), which met 
3-4 times/year, monitored the Phas e 2 studies listed above. On Oc tober 10, 2014 the FDA approved the 
combination product ledipasvir 90 mg/sofosbuvir 400mg called Harvoni. 
 SOF/LDV Fixed Dose Combination (FDC)  SOF/LDV fixed dose combination (FDC) tablets comb ine these 2 HCV specific direct acting antiviral 
(DAA) agents into a single tablet for the treatment of chronic HCV infection.  
 Please refer to the package insert for additiona l information on the SOF/LDV FDC including [40]: 
 In Vitro Anti-Hepatitis C Virus Activity Nonclinical Pharmacokinetics and In Vitro Metabolism Nonclinical Pharmaco logy and Toxicology 
Clinical Experience Summary of Additional Clinical Experience   Rationale for the Current Study Design The overarching goal of this study is  to provide the transplant commu nity with guidance on treatment 
strategies using sofosbuvir based DAA therapie s in patients with HI V-HCV pre and post-liver 
transplant. The study design includes both a re trospective and a pros pective component.  
 10-20 subjects will be enrolled in the prospective arm   designed to evaluate the efficacy and safety of 
the SOF/LDV FDC tablet, for treatment durations of 12 to 24 weeks, in chronic genotypes 1, 4, 5 & 6 in 
HIV/HCV coinfected subjects with pre or post liver transplant HCV. Pre-transplant subjects will be treated for 12 - 24 weeks or up to the time of liver transplant (LT) . Post-transplant subjects without 
cirrhosis will be treated for 12 weeks and post-transpla nt patients with cirrhosis  will be treated for 24 
weeks.  In addition, the safety and efficacy of  sofos buvir based DAA therapies wi ll be elucidated from 
retrospective data and contri bute to this goal.  Very little is known about the long-term benefits of DAA 
therapy in the transplant candidates and recipient, and the retrospective cohor t arm allows longitudinal 
follow-up of those who have been previously cure d with sofosbuvir based DAA therapy to determine 
rates of reversal of decompensa tion, reversal of cirrhosis and improvements in graft survival. 
 There is a significant unmet medical need for IFN-free all oral regime ns for the treatment of chronic 
HCV infection in HIV/HCV coinfection patients, particularly in patients with advanced disease and those with post-transplant hepatitis C given the toxi city and tolerability issues  associated with these 
medications, the unwillingness of many patients to be treated with PegIFN and/or RBV, as well as the 
 
Version 3.0  15 
7/11/2017 substantial numbers of patients who cannot receive PegIFN and/or  RBV due to contraindications 
[41].One such drug has been sofosbuvir, an NS5B inhibitor which in combination with IFN-based or 
IFN free regimens in several trials (1-3) has been  shown to be highly effe ctive. In HCV infected 
pretransplant patients, the use of sofosbuvir and ribavirin treatment prior to tran splantation prevented 
HCV recurrence in the majority of patients who were HCV R NA suppressed at transpla nt (4). In patients 
who developed recurrent hepatitis C post-transplant, the use of so fosbuvir and ribavirin showed 
promising early results with over 70% of patients achieving sustaine d virologic response 4 weeks post 
treatment (SVR 4). (5) FDC SOF/LDV for 12 weeks with or without ribavirin has been shown to be 
effective in HCV monoinfected patie nts with SVR rates of at least 95% [13-15]. Rates of SVR were 
slightly lower (86-88%) in treatme nt experienced patients with cirrh osis treated for 12 weeks but SVR 
increased to 100% with treatment for 24 week s. The ongoing NIAID SYNERGY trial of the FDC 
SOF/LDV has shown SVR12 rates of 100% in HCV- monoinfected subjects including cirrhotics (8). 
Drug interaction studies have been completed with several HIV antiretro virals and treatment trials of 
SOF/LDV in HIV/HCV coinfected subjects have b een initiated. The first of such is the NIAID 
ERADICATE study using the FDC of SOF/LDV in HIV/HCV coinfected subjects on or off 
antiretrovirals. In this stu dy, viral suppression occurred rapi dly, no major toxicities or HIV 
breakthroughs were observed and treatment was sa fe and well tolerated. 
 Rationale for Studying HI V/HCV Coinfected Subjects 
HIV/HCV coinfected subjects have lower rates of SVR when treated with combination therapy using 
PegIFN/RBV when compared to HCV monoinfected su bjects. HIV/HCV coinfect ed subjects also have 
faster rates of progression and a higher likelihood of developmen t of end stage liver disease and 
decompensated liver failure [26, 42]. DAAs that do not  rely on host immune system exclusively to 
abrogate HCV replication may be an  effective approach among HIV/HCV coinfected subjects regardless 
of race and IL28B genotype.  
 
Furthermore, use of RBV in HIV/HCV coinfected subjec ts is associated with an  increased incidence of 
anemia that requires dose reductions, interruptions and or treatment  with erythropoietin. All these 
increase the cost and adverse event profile of the therapeutic regimen. The de velopment of a treatment 
regimen without PegIFN/RBV for genotype 1 patients co-infected with  chronic HCV infection and HIV-
1 infection would allow for increa sed access to successful treatment to a significant proportion of the 
HCV-infected population. Safety, tolerability and efficacy of IFN fr ee regimens appear comparable 
between the HIV/HCV coinfected and HCV monoinfect ed subjects supporting th e evaluation of similar 
regimens to those under evaluation in HCV monoinfe ction. Furthermore, certain  studies suggest that 
patients with a robust immune status respond better to HCV therapy [43].  
  Overall Risk/Benefit Assessment The SOF/LDV FDC product combines a potent HCV nucleotide inhi bitor and a potent HCV NS5A 
inhibitor, and has the potential to  be a once-daily regime n for the treatment of chronic genotype 1 HCV 
infection.   The potential benefits of SOF/LDV FDC product for the treat ment of chronic HCV are: 
 Greater antiviral efficacy (i.e., rapid and durable eradication of HCV) compared to the current 
standard of care  
 
Version 3.0  16 
7/11/2017  A reduction in the AEs currently associated w ith the use of PegIFN, RBV, and/or available 
protease inhibitors (tel aprevir, boceprevir) 
 Shortened duration of therapy  
 Increased adherence to therapy with the c onvenience of a once daily, all oral, FDC   
 
The combination of sofosbuvir 400 mg and ledipasvir  90 mg has been administe red in studies to over 
2,500 subjects.  A review of the safety data from co mpleted studies shows that treatment with sofosbuvir 
and ledipasvir or FDC has been generally well tole rated.  No deaths or discontinuations of study drug 
due to AEs have been reported.  No Grade 4 or clinically relevant Grade 3 la boratory abnormalities have 
been reported.  No trends in vital sign change s have been observed fo llowing administration. The 
favorable safety and efficacy profiles of s upport further evaluation of this combination. 
 Postmarketing cases of symptomati c bradycardia, including fatal cardiac arrest and cases requiring 
pacemaker intervention have been reported when a miodarone is coadministered with SOF/LDV FDC. 
Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks 
after initiating HCV treatment. Pati ents also taking beta blockers, or those with underlying cardiac 
comorbidities and/or advanced live r disease may be at increased risk  for symptomatic bradycardia with 
coadministration of amiodarone. Br adycardia generally resolved after discontinuation of HCV treatment. 
The mechanism for this effect is unknown. Coadminis tration of amiodarone w ith SOF/LDV FDC is not 
recommended.    Rationale for the use of Interferon-free, all Oral Regimen HIV-infected subjects seem to have lower response s to HCV treatment using interferon based regimens. 
Since HIV infection is by itself an immunoregulatory disease, it is believ ed that these subjects will have 
less optimal responses to immune based therapies. However, use of non-immune based directly acting antiviral therapies that do not rely on host immu nity excessively, seem to work very well in HIV 
infected subjects. For example, HIV infected subj ects respond to antiretroviral therapy regardless of 
baseline CD4 T cell counts. Hence, it is expected that  HIV-infected subjects would have better rates of 
SVR when treated with non-immune based, directly acting agents for HCV. Second, we have previously 
demonstrated that HIV-infected subjects who contro l HIV replication by themse lves without the aid of 
ART seem to have faster clearance than those su bjects with similar CD4 T cell counts, but requiring 
ART to suppress HIV replication [28]. Third, we are using an extended treatment duration for these subjects (12 to 24 weeks). We believe this would allow us to maximize the rates of SVR for HIV 
infected pre and post liver transpla nt subjects in which relapse can be severe and associated with 
significant worsening of  decompensation.[44] 
 2.0 OBJECTIVES 
2.1 Primary Objectives  
 
1. To assess the safety, tolerabi lity, and efficacy of sofosbuvir based DAA therapy for 12 – 24 
weeks in HIV/HCV coinfected particip ants pre- and post- liver transplant. 
 
2. To assess the safety, tolerabilit y, and efficacy o
f a fixed dose co mbination (FDC) of sofosbuvir 
and ledipasvir (SOF/LDV) for 12 to 24 weeks in HIV/HCV coinfected participants pre or post 
liver transplant. 
 
Version 3.0  17 
7/11/2017 2.2 Secondary Objectives 
 
1. To evaluate changes in HCV vira l kinetics with SOF/LDV or so fosbuvir based DAA therapies in 
HIV/HCV coinfected subjects with pre or post liver transplant HCV 
 
2. To evaluate the proportion of subjects with HCV viral loads below the level of quantification at 
various time point s of the study 
 
3. To determine sustained virologic response ra tes with FDC SOF/LDV or sofosbuvir based DAA 
therapies.  
 
4. To identify the determinants of response to in terferon sparing therapy in eradicating HCV in pre 
or post liver transplant HI V/HCV coinfected subjects  
 
5. To identify the host genetic, protein, gene, and proteomic factors that are associated with 
responses to interferon (IFN) sparing therapy in in pre or post liver transplant HIV/HCV 
coinfected subjects (prospective arm only )  
 
6. To determine if levels of interferon-stimulate d genes (ISG) expression in PBMCs or liver can 
predict rapid virologic response (RVR), end of   treatment response (ETR), and sustained 
virologic response (SVR) in particip ants receiving IFN sparing therapy (prospective arm only)  
 
7. To evaluate the proportion of subjects whos e ALT normalizes during therapy and between 
baseline and SVR  
8. To evaluate the emergence of viral resistance during therapy with FDC SOF/LDV or sofosbuvir 
based DAA therapies  
9. To evaluate change in liver fi brosis and liver function before  and after treatment with FDC 
SOF/LDV or sofosbuvir  based DAA therapies. 
 
 3.0 STUDY
 DESCRIPTION 
Approximately fifty HIV/HCV coinfected patients w ith decompensated liver disease will be enrolled in 
the study. Ten (up to twenty) subjects will be treate d with FDC SOF/LDV pre or post liver transplant 
and followed prospectively. Forty + s ubjects will be enrolled retrospec tively with the intent to capture 
all patients who have been exposed to sofosbuvir based DAA therapies at pa rticipating sites since 
1/2014, and to mirror the population being enrolled prospectively.   In addition, participants in the re trospective arm will be contacted to  consent to one prospective study 
visit for liver staging to determin e rates of reversal of  decompensation, reversal of cirrhosis and 
improvements in graft survival post treatment, and fo r future contact by the NIH Clinical Center to 
assess longer term outcomes when this study ends.   
 
Version 3.0  18 
7/11/2017 3.1 Retrospective Arm 
Participating sites will collect clinical data on all of the HIV/HCV co-infected patients with 
decompensated liver disease (CPT >7 pre or post liv er transplant) treated w ith sofosbuvir based DAA 
therapies since 1/2014 at their center. This will be  done under IRB approved waiver of consent  if 
possible so that all treated patients meeting the inclusion criteria can be  included to avoid statistical bias. 
Data collected will mirror the data collected in the prospective arm. In addition, participants will be 
contacted to provide consent to return to the site for one visit for current li ver staging to evaluate 
reversal of fibrosis (unless liver  staging by Fibroscan or liver biopsy was done in the previous 12 
months),  and to be contacted in the future by the NIH Clinical  Center for long term follow-up. 
 
 Efficacy will be defined as HCV RNA undetectable ≥ 12 weeks post end of sofosbuvir based 
DAA therapy.  
 Safety and tolerability will be defined by  
o discontinuation rates 
o rates of hospitalization during DAA therapy 
o frequency of anemia requiri ng blood transfusion or EPO 
o survival. 
 Reversal of decompensation: de fined by CP score and MELD scor e at last follow-up (evaluated 
at time to event given th e variability in length of  follow-up post treatment) 
 Reversal of fibrosis: defined by liv er fibrosis by Fibroscan  or biopsy at last follow-up (evaluated 
at time to event given th e variability in length of  follow-up post treatment) 
3.2 Prospective Arm 
The cohort of pre-transplant patien ts with cirrhosis due to hepatitis  C will be treated with SOF/LDV 
until LT or for a maximum of 24 weeks. Patients w ith and without HCC within Milan criteria are 
eligible. Another cohort of liver transplant recipients with recurre nt HCV infection post  liver transplant 
will also be treated with SOF/LDV for a period of  12 weeks (no cirrhosis) or 24 weeks (cirrhosis). 
Patients with fibrosing cholestatic hepatitis are eligible and will be treated for 12 weeks. 
 Starting with Day 0, all subjects will receive SOF/LDV for 12 or up to  24 weeks. The total amount of 
time required to complete all the study visits is  approximately 56 - 68 week s from the screening period 
through the end of th e follow-up visits:  
 Up to 8 weeks Screening period 
 12 or 24 week treatment period  
 12 and 24 week post-treatment follo w-up visits (SVR12 and SVR24) 
 36 weeks post-treatment
  to assess late viral relapse 
Subjects identified to have mutations leading to  SOF or LDV resistance  following sequencing and 
phenotypic analysis will be requested to return at 12-week intervals for up to 36 weeks to determine the 
time required for the resistant viru s to return to background levels. 
  
 
Version 3.0  19 
7/11/2017 3.3 STUDY ENDPOINTS 
 
3.3.1 Primary Endpoints 
 Safety and tolerability of SOF/LDV for 12 to 24 weeks  
 Proportion of subjects achieving SVR 12 (HCV RNA <LLOQ 12 week s after completion of 
treatment) 
3.3.2 Secondary Endpoints 
 Correlation of the slope of HCV viral load de cline (early viral kinetics) with sustained 
virologic response at 24 weeks post-treatment (SVR 24) 
 Proportion of subjects achieving SVR 4 and SVR 24 (HCV RNA < LLOQ at 4 and 24 weeks 
after completion of treatment) 
 RVR 4, (RVR 4: HCV RNA<LLOQ at Week 4): Correlation of early viral kinetics with the 
percentage of subjects achieving RVR 4.  
 End of treatment response (ETR: HCV RNA<LL OQ at end of treatment). Correlation of 
early viral kinetics to the percenta ge of subjects who achieve ETR. 
 Correlation of early viral kinetics to the percentage of subjects who achieve SVR 12.  
 Viral relapse: Correlation of early viral kinetics with the percentage of subjects who develop 
viral relapse.  
 Differential interferon sensitive gene (ISR) resp onse to therapy in subjects treated for 12 
weeks who do and do not attain RVR 4 and SVR. 
 Host genetic and proteo mic factors in subjects with differential RVR 4 and SVR HCV 
quasispecies evaluation at baseline and during th erapy to determine emergence of resistance 
subjects who attain RVR 4, and those who achieve SVR.  
 HIV and HCV immunologic (adaptive and i nnate) correlates of SVR and RVR  
 Change in liver fibrosis before  and after treatment as determin ed by standard of care liver 
staging method. 
 
4 STATISTICAL  ANALYSIS 
4.1 Sample Size Requirements 
The sample size of 50 was chosen for 3 reasons:  
1. This is an achievable sample size given the number of known pool of HCV/HIV coinfected liver transplant candidates and recipien ts at the participating study s ites and the available time for 
recruitment. This sample size will also repres ent the largest experience with interferon- and 
ribavirin-free therapy in this specific population. In terms of the primary efficacy endpoint, 
combined (pre and post-transplant ) and separate analyses of SVR
12 will be estimated. Table 1 
shows the width of a 95% exact confiden ce interval for the probability of SVR 12 as a function of the 
number of SVRs in a sample size of 50. For instance,  if all 50 subjects have sustained virologic 
response, we can be 95% conf ident that the true SVR proba bility is between 0.929 and 1. 
 
 
 
Version 3.0  20 
7/11/2017 Table 1: SVR 12 Confidence Interval Table  
50 48 46 44 42 40 
0.929-1 0.863-0.995 0.808-0.978 0.757-0.955 0.709-0.928 0.663-0.900 
Exact 95% confidence interval  if the number of SVRs out of 25 is as shown in row 1. 
 
2. A sample size of 50 (pre and post-transplant) is sufficient to address the sa fety endpoints.  If the 
true event probability is 5% or  more, there is about a 92% chan ce of observing at least one such 
adverse event (Table 2).  Consequently, if no one ha s a given type of AE, we can be confident that 
its true probability is under 5%. This trial wi ll provide preliminary evidence on the safety and 
efficacy of FDC in pre or post liver tran splant HIV/HCV coinfected subjects.  
 
Table 2: Adverse Event Probability Table 
.01 .05 .10 .15 
39% 92%  99.5%  99.97%  
For AE probabilities shown in row 1, row 2 gives the probabilities of observing at least 1 
participant with the AE am ong 50 total participants. 
 
3. A sample size of 50 is adequate to support the mechanistic virologic a nd immunologic studies. 
4.1.1 Primary Endpoint 
The primary efficacy endpoint is SVR 12 (HCV RNA <LLOQ 12 weeks after cessation of therapy).  
4.1.2 Secondary Endpoints 
Secondary efficacy endpoints in clude: HCV RNA < LLOQ at 4 and 24 weeks after discontinuation of 
therapy (SVR 4 and SVR 24); viral breakthr ough; and relapse. 
4.1.3 Safety Endpoints 
The primary safety endpoint is any AE leading to permanent di scontinuation of study drug(s).  
4.1.4 Other Endpoints of Interest 
Additional efficacy evaluations may include HCV RNA change from Day 0; ALT normalization; and 
viral kinetic parameters. 
4.2 Analysis Populations 
Safety and efficacy will be ev aluated using the safety population. 
4.2.1 Efficacy Population 
The primary analysis population for efficacy analysis will be defined as all par ticipants who received at 
least one dose of study drug.  
4.2.2 Safety Population   
The primary analysis set fo r safety analyses will include subjects  who received at l east one dose of study 
drug. 
 
Version 3.0  21 
7/11/2017 On treatment data will be analyzed and defined as data collected from th e first dose of study drug 
through the date of last dose of study drug plus 30 days.  
4.3 Data Handling Conventions 
Missing data can have an impact upon the interpretation of the tria l data. Other than the endpoints 
discussed below, values for missi ng data will not be imputed.  
For the analysis of post-baseline ca tegorical efficacy endpoints, if a data  point is missing and is preceded 
and followed in time by values that are deemed succe sses, then the missing data point will be termed a 
success; otherwise the data point will be termed a failure. 
Any subject with missing data due to premature discontinuation of the study medication will be 
considered a failure at the time points on, or fo llowing, the date of di scontinuation. If no HCV RNA 
values are obtained after the last  dose of study medication, the subject will be c onsidered a treatment 
failure for the SVR endpoints.  
Where appropriate, safety data for subjects that did not complete the study will be included in summary 
statistics. For example, 
 If a subject received study medication, the subject w ill be included in a summary of adverse events 
according to the treatment received; otherwise, if the subject is not dosed then they will be excluded 
from the summary. 
 If safety laboratory results for a subject are missing for any reason at a time poi nt, the subject will be 
excluded from the calculation of su mmary statistics for that time point. If the subject is missing a 
pre-dose value, then the subject will be excluded fro m the calculation of summary statistics for the 
pre-dose value and the change from pre-dose values. 
Values for missing vital signs data will not be imputed ; however, a missing Day 0 result will be replaced 
with a screening result, if available. 
4.4 Efficacy Analyses 
4.4.1 Primary Analysis 
The primary efficacy endpoint is SVR 12 (HCV RNA <LLOQ 12 weeks af ter cessation of therapy.)  
There is no active comparator group fo r this study (as in most clinical trials with all oral therapies in 
these populations).  
 In the primary efficacy analysis, an exact Clopper-P earson 95% confidence interval will be computed 
for the SVR
12 rate. 
 The primary analysis will be perf ormed after all enrolled subjects ha ve been followed through 12 weeks 
post-treatment or discontinued from study. 
 
Version 3.0  22 
7/11/2017 4.4.2 Secondary Analysis 
The proportion of subjects with HCV RNA below the LLOQ over time (including SVR endpoints) will 
be presented.  
Descriptive summaries and listings will be provided for additional efficacy evaluations of the proportion 
of subjects who experience virologic failure and other endpoin ts of interest including ALT 
normalization, plasma HCV RNA actu al values, and change from ba seline. Heterogeneity among the 
study populations (pre- versus post-tr ansplant, severity of liver dise ase, type of ARVs, baseline 
characteristics and others) and limited sample size will preclude us from performing extensive multivariate models to determine predic tors of treatment success or failure.  
Exploratory regression analyses ma y be performed to assess the re lationship between demographic, 
baseline characteristics, (incl uding baseline viral load, genotyp e, age, sex, race, ethnicity, 
presence/absence of cirrhosis, baseline ALT level, prior treatment experience, response to previous 
treatment [if applicable], and BMI) and antiviral activity (as measured by HCV RNA log reduction).  
Details on efficacy analyses will be described in the statistical analysis plan. 
4.5 Safety Analysis 
Safety will be evaluated by assessment of clinical laboratory tests, phys ical examinations, and vital signs 
measurements at vari ous time points during th e study, as well as the documentation of AEs. 
5 PATIENT
 POPULATIONS 
5.1 Retrospective Arm Inclusion Criteria  
The intent of the Retrospective Arm is to capt ure all HIV/HCV coinfected patients exposed to 
sofosbuvir based DAA therapy since 2014, to mirror the population enrolled in the Prospective Arm. 
 Liver transplant candidates (listed)   and decompensated cirrhotics ( not listed) for liver transplant 
1. Treated with sofosbuvir based DAA for any duration since 2014  
2. Age >18 years at time of treatment 
3. Pre-treatment Child’s Pugh score of 7 or greater  
4. Pre-treatment laboratory MELD ≥6 and ≤ 30 
5. Survived at least 12 weeks after start of treatment 
6. HIV-positive on stable ART for at least 4 weeks pre-treatment 
7. Chronic HCV infection with at least one measurement of plasma HCV RNA ≥ 1,000 
IU/mL prior to treatment with  sofosbuvir based DAA therapy 
8. HCV genotype 1, 4, 5 or 6  
Liver transplant recipients 
1. Treated with sofosbuvir base d DAA post liver transplant for any duration since 2014 
2. Liver transplant from  2000 to current 
3. Age >18 years at time of treatment 
4. Treated initiated at least 1 m onth  post-liver transplant  
5. Post-LT stage of liver disease documented with in the prior year  of treatment start date 
by standard of care meth ods of liver staging 
6. Survived at least 12 weeks after start of treatment 
 
Version 3.0  23 
7/11/2017 7. HIV-positive on stable ART for at least 4 weeks pre-treatment 
8. Chronic HCV infection with  at leas t one measurement of plasma HCV RNA ≥ 1,000 
IU/mL prior to treatment with  sofosbuvir based DAA therapy 
9. Fibrosis staging done within 1 year of start of DAA therapy 
10. HCV genotype 1, 4, 5 or 6  
5.2 Prospective Arm Inclusion/Exclusion Criteria 
  Pre-liver transplant candidates 
‐ Enrollment will be targeted to occur at least 12 weeks prior to anticipated transplant date. 
‐ Screening laboratory MELD ≥6 and ≤ 20 (NIH) or ≤30 (non-NIH sites) 
Post-liver transplant recipients 
‐ Recipients with evidence of recurrent HCV viremia  
‐ Subjects with compensated and decompensated liver disease 
‐ Screening laboratory MELD ≥6 and ≤ 20 (NIH) or ≤30 (non-NIH sites) 
‐ Life expectation of >12 weeks 
 
Inclusion  Criteria 
1. Over 18 years of age at screening 
2. Female participants of child bearing potential mu st have a negative urine pregnancy test at day 0 
prior to dosing. 
3. Has received a liver transplant for HCV or has decompensated cirrhosis (Child’s Pugh score of 7 
or greater) 
4. Have HIV-1 infection and either: 
a) On HIV medications (antiretrovira ls) for at least 4 weeks WITH 
 An HIV viral load less than the level of detection OR 
b) On no HIV medications for at least 8 weeks WITH: 
 A CD4 count of 500 cells/mm3 or more OR 
 HIV viral load of < 500 c opies/mL with a stable CD4 count for at least  3 months  
5. Chronic HCV infection as documented by at l east one measurement of plasma  HCV RNA ≥ 1,000 
IU/mL during screeni ng and at least one of the following: 
A positive anti-HCV antibody, HCV RNA, or an HCV genotype test at least 12 months prior to 
baseline (Day 0) visit together with positive HCV RNA test 
6. HCV genotype 1, 4, 5 or 6 
7. The use of an anti-HCV positive donor is allowed for participants who have detectable HCV RNA 
at the time of transplant. 
8. The use of an HIV+ donor is allowed if the participant is enrolled in an IRB approved HOPE Act protocol at the transplant  site. If the HIV+ donor is also HCV co-infected, then th e recipient must 
have detectable HCV RNA at the time of transplant. 
9. Able to effectively communicate with th e Investigator and ot her center personnel. 
10. Willing to give written informed  consent and comply with the study restricti ons and requirements. 
11. Willingness to allow stored blood or tissue samples to be used in  the future for studying liver 
 
Version 3.0  24 
7/11/2017 disease and immune function. 
12. Willingness to permit HLA typing to be performed. 
13. Have a transplant team available for all primary and transplant-related care.  
14. If not yet transplanted: expected to  be at least 12 weeks prior to tr ansplant in order to complete 
treatment course.  
15. If not yet transplanted: Must have prior standa rd of care liver stagi ng consistent with F4. 
16. If not yet transplanted: For pre-LT patients with HCC, they must m eet Milan criteria at time of 
enrollment to be eligible 
17. If  post-liver transplant, must be at least 1 month since transplant  procedure to begin treatment.  
18. If post-liver transplant, liver dise ase staging must be documented w ithin the prior y ear by standard 
of care methods of liver staging  
 
Exclusion Criteria 
1. Positive HBsAg or anti-HBc at screening.  
2. History of any other clinically active chronic liver disease (e.g., hemochromatosis, autoimmune 
hepatitis, Wilson’s disease, 1-antitrypsin deficiency, alcoholic liver disease,  and toxin exposures). 
3. Treatment with unlicensed herbal/natural remedies  suggested to be taken for hepatitis treatment, 
such as Milk thistle, St. Johns Wort or Cats  Claw, within 28 days of start of treatment 
4. Treatment with IFN, RBV, telaprevir or bocepre vir or any other approv ed or experimental 
medication with known anti-HCV  activity within 1 month pr ior to screening date  
5.  Any prior exposure to an HC V NS5a specific inhibitor  
6. A personal history of or firs t degree relative with a hi story of Torsad e de pointes. 
7. Abnormal hematological and bioche mical parameters, including: 
a. Hemoglobin < 8g/dL 
b. Estimated GFR, calculated by the CKD-EPI equation, <30 mL/min/ per 1.73 m2 
c. Sodium <120 mmol/L 
8. History of major organ transplantation other than liver or  kidney transplantation.  
9. Difficulty with blood collection/poor venous access for phlebotomy  that would prevent the 
collection of study required samples 
10. Infection requiring systemic antibio tics at the time of screening  
11. Active or recent history ( ≤ 6 months) of drug or alcohol abuse 
12. Gastrointestinal disorder or  post-operative condition that could interfere  with the  
absorption of the study drug. 
13. Donation or loss of more than 400 mL blood within  8 weeks prior to firs t dose administration. 
14. Any medications prohibited (see table 2 in sec tion 8.11) within 28 days pr ior to Day 0 visit and 
likely required during study treatment period 
15. History of clinically sign ificant drug allergy to nucl eoside/nucleotide analogs.  
 
Version 3.0  25 
7/11/2017 16. History or current evidence of psychiatric illne ss, endocrine, immunologic disorder, pulmonary, 
cardiac disease, seizure disorder, ca ncer or other conditions that in the opinion of the investigator 
makes the patient unsuitable for the study. Chronic medical conditions, especi ally if treated with 
medications (such as hypertension) , must be stable at the time of screening.  No new therapies 
should be started within 28 days prior to the study th at may confound the asse ssment of study drug 
safety. 
17. Participation in a clinical st udy (other than an IRB approved HOPE Act protocol involving the 
utilization of an HIV+ donor)  in which an invest igational drug, biologic, or device was received 
within 12 weeks prior to first dose administration. 
18. Pregnant/Breastfeeding women  
 
 
6 SCHEDULE  OF VISITS  AND  PROCEDURES:  RETROSPECTIVE  ARM 
6.1 Waiver of Consent 
In order to capture all eligible candidates in the retrospective arm,  data will be captured under an IRB 
approved waiver of consent if site s obtain IRB approval to do so.  
6.2 Consent for liver staging and long term follow-up 
If participants can be contacted, they will be asked if  they would consent to return for one study visit for 
current liver staging unless standa rd of care liver staging by Fibr oscan or liver biopsy has been 
performed within 12 months. Each subject will provide informed consent prior to commencement of any 
study procedures according to ICH and Code of Fe deral Regulations (CFR).  Each subject will be 
provided a copy of the signed informed consent form . The consent will also include approval to be 
contacted in the future by the NIH and/or co-i nvestigators for additiona l longer term follow-up. 
6.3 Time-points 
Clinical data from day 0 (start of treatment), we ek 4, and end of treatment (week 12 or 24 depending on 
treatment duration) will be recorded in the Redcap da tabase. Data will also be recorded at 3 months post 
treatment with DAA and again at 6 or more months post treatment wi th DAA. A complete list of study 
procedures to be captured is outlined in the Schedule of Events (Section 11) 
 
 7 SCHEDULE
 OF VISITS  AND  PROCEDURES:  PROSPECTIVE  ARM 
Participants will be seen on each study visit at the enrolling center. A complete list of study procedures 
to be performed is in the Sc hedule of Events (Section 11). 
7.1 Screening (Visit 1) 
Each subject will provide informed consent prior to commencement of any study procedures according 
to ICH and Code of Federal Regulations (CFR).  Each subject will be provided a copy of the signed informed consent form.   
 
Version 3.0  26 
7/11/2017 After a subject has provided informed consent, screening evaluations will be conducted and the 
investigator and other study personnel will determine if the subject is eligible fo r participation in the 
study. Screening will include a review of the medical history, inclusion/exclusion criteria, concomitant 
medications, physical examination, and bl ood tests.  Screening tests that ha ve been done as part of other 
studies or at an outside facility can be used if within the acceptable time frame (applicable lab tests 
within 56 days before enroll ment). Some tests in the schedule of ev ents allow the use of historic data to 
be used, such as the virology panel, HIV VL, CD4+  T-cell count, and HLA. These have been marked 
accordingly in the schedule of events. 
  Screening procedures do not need to  be repeated within the 8 week screening window unl ess clinically 
indicated. 
7.2 Liver Staging (Screening) 
All pre-transplant subjects must ha ve prior standard of care liver st aging consistent with F4. All post-
transplant subjects must have stage of liver disease documented within the prior year by standard of care 
liver staging methods.  
7.3 Physical Examination, including vitals signs 
All participants will have a physical visit for the final determination of protocol eligibility.  In addition, 
participants will have a physical examination performed at the foll owing time points: Day 0, week 4, 
week 12 and (if applicable) week 24 on treatment and at 6 months post treatment visits. A targeted physical exam will be performed on partic ipants as needed for AE evaluation.  
7.4 Starting SOF/LDV (Visit 2) 
The participant will be started on SOF/LDV on Visit 2 (Day 0).  For wait-listed patients, treatment start 
date should coincide with an anticipate time to tran splant of at least 12 weeks (based on MELD score).  
 Blood will be drawn for standard of care labs and for research (HCV viral loads, drug level, 
immunologic studies, and for storage) . For women with childbearing pote ntial, a urine pregnancy test 
will be done on Day 0 and must be negative prior to dosing with study agent. The Day 0 procedures are 
summarized in Schedule of Events  (Section 11).  
7.5 Adverse event assessment and concomitant medications 
At each visit, participants will be asked about th eir state of health and use of any concomitant 
medication since screening or the pr evious study visit.  They will also  be questioned about AEs and their 
adherence with study restrictions. In addition, participants will be seen at unscheduled visits for a grade 
3 or 4 AE or any unexpected AE (adv erse event) or pot ential toxicity.  
7.6 Study Visits during treatment 
 All participants will be seen on days 0, weeks 4, and week 12 EOT, (or week 24 if treated for 24 wks).  
 Weeks 4 (+/- 7 days) 
 Week 12 [and 16, 20, 24 if applicable] (+/- 10 days) 
 
 
Version 3.0  27 
7/11/2017 Plasma HCV RNA will be obtained on each visi t. Subjects who fail to achieve >2 log 10 HCV RNA drop 
at this time (unless >2 log drop would be belo w LLOQ) will be discontinued from therapy unless a 
review by the PI/Operations Committee determines otherwise. 
7.7 Week 12 or 24 Visit / End of Treatment Visit 
Week 12 or 24 will mark the last dose of SOF/LDV to be administered. In addition, if a subject’s 
participation terminates prior to end of treatment,  the assessments may be performed at any end-of-
treatment visit.  
7.7.1 Liver Staging (End of Treatment) :  
All subjects will have end of treatment liver staging by the same method used to stage at 
screening.  
7.8 Day of Transplant (for Pre-Transplant subjects): Liver Explant Tissue 
Subjects who receive treatment pre-transplant and achieve SVR, but who nonetheless progress to liver 
transplantation, will have a portion of the explanted liver snap frozen or placed in RNA- later on the 
day of transplant. See Laborator y Manual for processing protocol. 
7.9 Post treatment follow up visits 
After discontinuation of the study dr ug, subjects will be followed at post-treatment Week 12 and 24. The 
visit windows are shown below 
 Follow up visits (+/- 14 days) 
 Post treatment optional liver biopsy -7 days / +3 0 days (but can be done outside this window at 
the investigator’s or physician designee’s discretion). 
7.10 Early Termination and Early Treatment Discontinuation 
Participants who elect to disconti nue study drugs prior to treatment completion for medical or personal 
reasons will be given the option of being followed up at least every 12 weeks for safety and research 
labs until the end of the study. The participan t should have an end of treatme nt visit scheduled as soon as 
possible after all therapy is disc ontinued. Participants with undetectable HCV RNA at the end of 
treatment should continue to follow the scheduled SVR visits following th e date of their last dose of 
therapy.   For the prospective arm, participan ts who have detectable HCV RNA at the end of treatment or who 
relapse post-treatment will be asked to return for visits to determine the persistence of any HCV 
populations with treatment-emergent substitutions conf erring resistance to sofosbuvir. Samples collected 
will be used to determine the dur ability of response or the dynamic s of any changes in resistance 
conferring mutations. The r eason for any early terminat ion should be documented. 
 8 STUDY
 AGENT/INTERVENTIONS:  PROSPECTIVE  ARM 
8.1 Disposition and Dispensation 
Study agents will be distributed via the UCSF Inve stigational Pharmacy according to standard 
pharmacy procedures.  
 
Version 3.0  28 
7/11/2017 All drug products will be stored in  a securely locked area, accessible only to authorized site personnel. 
To ensure the stability of the study drug and to ensure proper product identif ication, the drug product 
should not be stored in a container other than the container in which they are supplied. Consideration 
will be given to handling, preparation, and disposal  through measures that mi nimize drug contact with 
the body. Appropriate precautions will be followed to avoid direct eye contact or exposure through 
inhalation when handling study drugs. 
8.2 Packaging and Labeling of Study Drugs 
Each bottle will be individually labeled with the pa tient ID number, dosing instructions, recommended 
storage conditions, the name and address of  the manufacturer, Investigational Use 
Statement (“Caution: New Drug – Limited by Federal [USA] Law to Investigational Use”) and that 
the agent should be kept out  of reach of children. 
8.3 Formulation of FDC SOF/LDV 
SOF/LDV fixed dose combination (FDC) tablets ar e orange colored, diam ond-shaped, film-coated 
talets containing 400 mg of sofos buvir and 90 mg of ledipasvir. Th e tablets are debossed with “GSI” 
onone side and “7985” on the other side. The SOF/L DV FDC tablets contain th e following inactive 
inredients: lactose monohydrate, copovidone, micro crystalline cellulose, croscarmellose sodium, 
colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, tita nium dioxide, talc, polyethylene 
glycol, FD&C yellow # 6 /sunset  yellow FCF aluminum lake. 
8.4 Storage And Handling of FDC SOF/LDV  
SOF/LDV FDC bottles should be stored at  room temperature below 30°C (86°F). 
8.5 Dosage and Administra tion of FDC SOF/LDV 
SOF/LDV FDC tablet is to be admi nistered once daily with  or without food. Each subject must be 
given instructions to maintain a pproximately the same daily dosing interval between study drug doses. 
For missed dose(s) of study medication, subjects will be  instructed to take th e missed dose(s) of study 
medication as soon as possible during the same day.  Subjects will be cautioned never to double the 
next dose with a missed dose of study drug under any circumstances. 
8.6 Treatment of Participants  
All participants will receive 12 or up to 24 weeks of SOF/LDV. SOF/LDV will be administered as a 
single pill at dose of 400 mg and 90 mg respectively orally once a day. It can be taken with or without 
food. 
If a participant who starts treatment with study drug prior to transp lant receives 4 week s of treatment or 
less prior to transplant and has detectable HCV at ti me of transplant, they are eligible to receive full 
treatment post-transplant. 
If a participant who starts treatment with study drug prior to tran splant has received more than 4 weeks 
of treatment prior to transplant, they are NOT el igible to receive full treatment post-transplant, 
regardless of HCV RNA level at the time of liver tran splantation. Therefore,  study treatment is 
discontinued at the ti me of transplant. 
 
Version 3.0  29 
7/11/2017 8.7 Dose Modifications/Toxicities 
Maximal suppression of HCV replication is most lik ely accomplished by sustained delivery of antiviral 
agents at their current recommend ed doses. Dose reduction, however, would compromise this goal and 
predispose to the emergence of drug-resistant viral variants.  Hence, no dose reduction will be allowed for SOF/LDV. If SOF/LDVis stopped due to toxicity, it must not  be restarted. 
 If treatment with study drug is interr upted for <= 5 consecutive days for reasons other than drug toxicity 
(such as discontinuation due to GFR < 30), treatment ca n be reinitiated and the s ubject can remain in the 
trial. However, if treatment is in terrupted for > 5 days and/or if st udy drug is interrupted due to drug 
toxicity, treatment with study drug should be discontinued. 
8.8 Dose Modification for SOF/LDV 
SOF/LDV dose modifications will not be permitted. If subject meets safety or virologic criteria for 
discontinuation, the SOF/LDV will be stopped.   If a subj ect forgets to take the medication at the correct 
time, it may be taken later in th e day; however, no more than a single dose should be taken on any 
calendar day. The subject should resume the standi ng dosing schedule on the ne xt day.  Any treatment 
interruption or discontin uation will be recorded including th e reason for the interruption or 
discontinuation.  
8.9 Criteria Requiring Disc ontinuation of SOF/LDV 
Subjects will be considered treatment failures and will discontinue SOF/LDV if  they meet any of the 
following criteria while taking study drugs: 
 Plasma HCV RNA greater than LLOQ after 2 prior consecutive HCV RNA values less 
than the LLOQ 
 Greater than a 1 log
10 increase in plasma HCV RNA from nadir 
 Less than a 2 log 10 decline in HCV RNA after 4 weeks of treatment 
 
If any of these should occur in a subjects who is currently on study drugs, the subject should return 
within one week for a confirmatory test. If the confirmatory test also meets the same crit eria, the subject 
will be considered a treatment failure and should be  discontinued from therapy.  Participants will be 
referred for other treatmen t options. The anticipated clinical impact of discontinuation should be 
discussed in advance if possible, particularly if discontinuation is thought to pose a ri sk to the overall 
clinical wellbeing of the subject.  Those who are discontinued will co ntinue to follow the general study 
schedule of assessments unless unwil ling to do so, in which case they  may be seen at least every 12 
weeks for safety and research la bs until the end of the study.  Subj ects will be followed closely for 
resolution of active laboratory abnormalities or adverse events that are considered related to the study 
agents prior to starti ng the revised schedule. 
 Subjects who meet any of the following laboratory criteria mu st stop all study medication(s): 
 Any Grade 3 or greater rash associated with constitutional symptoms 
 Any Grade 4 event assessed as possibly, probably, or definitely related to treatment with 
SOF or LDV 
 
Version 3.0  30 
7/11/2017 8.9.1 Treatment Failure Criteria After Stopping SOF/LDV  
 Have detectable HCV RNA during the post-tr eatment period (after having achieved HCV 
RNA <LLOQ at end of treatment). 
8.10 HIV Virologic Rebound Crit eria for Subjects on ARVs 
Subjects on ARVs who have at least 2 consecutive post-Day-0 vi sit plasma HIV-1 RNA levels ≥  
1000 copies/mL (at least 2 weeks apart) will be considered to  have HIV virologic rebound.  
Following an initial HIV-1 RNA result of ≥ 1000 copies/mL, subjects on ARVs will be asked to return 
to the clinic after 2 weeks for a scheduled or unsch eduled blood draw for confirmation of HIV virologic 
rebound. If HIV virologic rebound is conf irmed, the blood samples from th is visit will be used for 
HIV-1 genotype/phenotype testing. If no resistance to the subject’s curr ent ARV regimen is detected, the 
subject may continue on current ARV regimen.   
HCV study drug should be continued unless safety ev ents warrant the discon tinuation of these study 
drugs, as outlined in sect ion 9.2 of the protocol. 
8.11 Concomitant Medications 
Concomitant medications taken within 30 days of screening through 30 days following discontinuation 
of study treatment need to be recorded in the source documents. 
The medications listed in Table 2 ar e prohibited from 28 days prior to the Day 0 (start of treatment) visit 
through the end of treatment: 
 Concomitant use of certain medications or herbal/n atural supplements (inhibitors or inducers of drug 
transporters i.e., P-gp) with st udy drug(s) may result in pharmacoki netic interactions resulting in 
increases or decreases in exposur e of study drug(s).  Examples of representative medications which 
are prohibited from 28 days prior to  Day 0 (start of trea tment) through the end of treatment are listed 
below: 
 Medications for disease conditions excluded  from the protocol  are not listed under this Concomitant 
Medication section and are disallowed in the study.  
Note: Since this table is likely to change over ti me, please review the most current package inserts 
before prescribing new drugs or modify ing doses of concomitant medications. 
Table 2: Potentially Significant Drug Interact ions: Alteration in Dose or Regimen May be 
Recommended Based on Drug Interaction Studies or Predicted Interactionsa 
 
Concomitant Drug Class: Drug Name Clinical Comment  
Acid Reducing Agents Ledipasvir solubility decreases as pH incr eases. Drugs that increase gastric pH are 
expected to decrease concentration of ledipasvir. 
Antacids (e.g., aluminum  and 
magnesium  hydroxide)  It is recommended to separate antacid and HARVONI administration by 4 hours. 
 
Version 3.0  31 
7/11/2017 H2-receptor antagonistsb  (e.g., 
famotidine)  H2-receptor antagonists may be administered simultaneously with or 12 hours apart 
from HARVONI at a dose that does not exceed doses comparable to famotidine 40 mg twice daily.  
Proton-pump inhibitorsb (e.g., 
omeprazole)  Proton-pump inhibitor doses comparable to omeprazole 20 mg or lower can be 
administered simultaneously with HARVONI under fasted conditions.  
Antiarrhythmics : 
digoxin amiodarone Coadministration of HARVONI with digoxin may increase  the concentration of 
digoxin. Therapeutic concentration monitoring of digoxin is recommended when 
coadministered with HARVONI. Coadministration of HARVONI with amiodarone 
may result in serious symptomatic bradycar dia. The mechanism of this effect is 
unknown. Coadministration of amiodarone with HARVONI is not recommended; if coadministration is required, cardiac monitoring is recommended . 
Anticonvulsants:  carbamazepine  
phenytoin  
phenobarbital  oxcarbazepine 
 Coadministration of HARVONI with carbam azepine, phenytoin, phenobarbital, or 
oxcarbazepine is expected to decrease the concentration of ledipasvir and 
sofosbuvir, leading to reduced therapeutic  effect of HARVONI. Coadministration 
is not recommended.  
Antimycobacterials:  
rifabutin  
rifampinb  
rifapentine  Coadministration of HARVONI with rifabu tin or rifapentine is expected to 
decrease the concentration of ledipasvir and sofosbuvir, leading to reduced 
therapeutic effect of HARVONI. Coadministration is not recommended. Coadministration of HARVONI with ri fampin, a P-gp inducer, is not 
recommended 
HIV Antiretrovirals  
efavirenz,  
emtricitabine,  
tenofovir disoproxil  
fumarate (DF)  Monitor for tenofovir-associ ated adverse reactions in patients receiving HARVONI 
concomitantly with the combination of ef avirenz, emtricitabine and tenofovir DF. 
Refer to VIREAD, TRUVADA, or ATRIPLA prescribing information for 
recommendations on renal monitoring.  
Regimens containing  tenofovir DF and a HIV protease inhibitor/ritonavir  
 atazanavir/ritonavir + 
emtricitabine/tenofovir DF
b 
 darunavir/ritonavir + emtricitabine/tenofovir DF
b 
 lopinavir/ritonavir + emtricitabine/tenofovir DF The safety of increased tenofovir concen trations in the setting of HARVONI and a 
HIV protease inhibitor/ritonavir  has not been established. Consider alternative 
HCV or antiretroviral therapy to avoid  increases in tenofovir exposures. If  
coadministration is necessary, monitor for tenofovir-associated adverse  reactions. 
Refer to VIREAD or TRUVADA prescribing information for recommendations on 
renal monitoring. 
elvitegravir, cobicistat,  
emtricitabine, tenofovir  
DF  The safety of increased te nofovir concentrations in the setting of HARVONI and 
the combination of elvitegravir,  cobicistat, emtricitabine and tenofovir DF has not 
been  established. Coadministration is not recommended.  
tipranavir/ritonavir Coadministration of HARVONI with tipranavi r/ritonavir is expected to decrease 
the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI. Coadministration is not recommended.  
HCV Products:  
Simeprevirb 
  Concentrations of ledipasvir and simepr evir are increased when simeprevir is 
coadministered with ledipasvir. Coadmini stration of HARVONI with simeprevir is 
not recommended.  
Herbal Supplements: 
St. John’s wort (Hypericum perforatum)  Coadministration of HARVONI with St. John’s wort, a P-gp  inducer is not 
recommended 
 
Version 3.0  32 
7/11/2017 HMG-CoA Reductase Inhibitors 
rosuvastatin Coadministration of HARVONI with rosuvastatin may significantly increase the 
concentration of rosuvastatin which is asso ciated with increased  risk of myopathy, 
including rhabdomyolysis. Coadministration of HARVONI with rosuvastatin is not 
recommended.  
a.This table is not all inclusive.  b. These interactions have been studied in healthy adults.  
 
9 EVALUATION  OF SAFETY   
All enrolled subjects who have received SOF/LDV will be evaluated for safety. Safety will be assessed 
by physical examination, vital signs, hematology, and chemistries. The se verity of signs, symptoms, and 
AEs will be determined by using the 2014 DAIDS Table for Grading the Severity of Adult and Pediatric 
Adverse Events, with edits made to a llow for clinical center normal values. 
9.1 Follow-up of Abnormal Laboratory Test Values 
In the event of unexplained abnormal laboratory test values, the tests should be repeated as soon as 
possible and followed up until they have returned to th e normal range and/or an adequate explanation of 
the abnormality is found.  If a clear explanation is establis hed it should be recorded.  
9.2   Criteria for Premature Withdrawal and Stopping Rules  
Subjects have the right to withdraw  from the study at any time for any reason.  Subjec ts who withdraw 
early or who are terminated from study by the Inve stigator will not be replaced unless they have 
received no study drugs.  In addition to the criteria for stopping subjec t treatment described in section 
8.9, the Investigator or designee also  has the right to withdraw subj ects from the study for any of the 
following: 
1. Participant’s desire to leave study. 
2. Pregnancy or breastfeeding.  
3. Participant’s non-compliance. If a subject misses 5 or more total study visits or > 3 weeks of 
study drug, the subject will be removed from the protocol by the study team. 
4. Termination of study. 
5. Development of a medical condition that in the opinion of the Inve stigator, it is in the subject’s 
best interest to discontinue st udy drug even if criteria requiri ng drug discontinuation have not 
been met. 
6. Request of the primary care provider or Investigator if  s/he thinks the stud y is no longer in the 
best interest of the subject.  
7. Clinical reasons believed life threatening by the physician.  
 
 
10 ADVERSE  EVENT  REPORTING  AND  MONITORING 
10.1   Definitions 
 Adverse Event (AE): Any untoward or unfavorable medical o ccurrence in a human subject, including 
any abnormal sign (e.g. abnormal physical  exam or laboratory finding), sy mptom, or disease, temporally 
associated with the subject’s participation in the research, whether or not considered related to the 
research  
 
Version 3.0  33 
7/11/2017 Adverse Reaction (AR):  An adverse event that is caused by a drug. 
 
Suspected Adverse Reaction (SAR):  An adverse event for which there is a reasonable possibility that the drug caused the adverse event. ‘Reasonable possibi lity’ means that there is evidence to suggest a 
causal relationship between the drug and the advers e event. A suspected adverse reaction implies a 
lesser degree of certainty about cau sality than adverse reaction, which implies a high degree of certainty. 
 Serious Adverse Event (SAE) :  
A Serious Adverse Event is an AE that result s in one or more of the following outcomes: 
 
 death 
 a life threatening (i.e., an imm ediate threat to life) event 
 an inpatient hospitalization or prolon gation of an existing hospitalization 
 a persistent or significan t incapacity or substantia l disruption of the ability to conduct normal life 
functions 
 a congenital anomaly/birth defect 
 a medically important event* 
 Medical and scientific judgment should be exer cised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events th at may not be immediately life 
threatening or result in death or hospitalization but they may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed above. 
  Unexpected Adverse Event:  An AE is unexpected if it is not listed in the package insert or is not listed 
at the specificity or sever ity that has been observed.  It is the re sponsibility of the Sponsor to make this 
determination.  
 Serious and Unexpected Suspected Adverse Reaction (SUSAR):  A SUSAR is a Suspected Adverse 
Reaction that is both Serious and Unexpected.    Unanticipated Problem (UP):  Any incident, experience,  or outcome that is 
1.    unexpected in terms of nature, severity, or frequency in relation to 
a. the research risks that are descri bed in the IRB-approved research  
protocol and informed consent document; pa ckage insert or other study documents; and 
b.    the characteristics of the s ubject population bei ng studied; and 
2.   related or possibly related to participation in the research; and 3.   places participants or others at a greater risk  of harm (including physical, psychological, economic, 
or social harm) than was previous ly known or recognized.  (Per the st udy sponsor, an adverse event with 
a serious outcome will be considered increased risk.) 
 
Unanticipated Problem That Is Not An Adverse Event (UPnonAE): An incident, experience or outcome that is not associated w ith an adverse event which meets th e 3 criteria of a UP.  Examples 
include occurrences of breaches of confidentiality , accidental destruction of study records, and 
unaccounted-for study drug  Protocol Deviation: 
 
Version 3.0  34 
7/11/2017 Any change, divergence, or departure from the IRB approved study procedures in  a research protocol. 
Protocol deviations are designa ted as serious or non-serious and further characterized as: 
 Those that occur because a member of the re search team deviates  from the protocol. 
 Those that are identified before th ey occur, but cannot be prevented. 
 Those that are discovered after they occur 
 
Serious Protocol Deviation: A deviation that meets the definition of a Serious Adverse Event or 
compromises the safety, welfare or rights of subjects or others.  Non-compliance: The failure to comply with applicable NIH HRPP policies, IRB requirements, or regulatory requirements for the prot ection of human subjects. Non-compliance is further characterized 
as 
1. Serious: Non-compliance that: 
a. Increases risks, or cause s harm, to participants 
b. Decreases potential benefits to participants 
c. Compromises the integrity of the NIH-HRPP 
d. Invalidates the study data 
2. Continuing: Non-compliance that is recurring 
3. Minor: Non-compliance that, is ne ither serious nor continuing. 
10.2   Assessing Adverse Events 
If a diagnosis is clinically evident,  the diagnosis rather than the individual signs and symptoms or lab 
abnormalities will be re corded as the AE. 
 All grade 3 or higher AEs occurring from the time tr eatment starts on Day 0 and through the specified 
study follow-up period will be documented, recorded, a nd reported. The Investigator will evaluate all 
AEs with respect to Seriousness (cr iteria listed above), Severity (int ensity or grade), and Causality 
(relationship to study agent and relationship to research) according to the following guidelines.  
10.3 Severity Grading 
Severity of AEs will be graded ac cording to the “Division Of AIDS Table For Grading The Severity Of 
Adult And Pediatric Adverse Even ts” (Version 2.0, November, 2014). 
Adverse Events not found in the Toxi city Table will be assessed for severity and classified into one of 
the categories below: 
 Grade 1 (Mild): Event requires minimal or no treatment a nd do not interfere with the participant’s 
daily activities. 
 Grade 2 (Moderate) : Event results in a low level of inconvenience or concern with the 
therapeutic measures.  Modera te events may cause some interference with functioning. 
 Grade 3 (Severe) : Event interrupts a subject’ s usual daily activity or functioning and may require 
systemic drug therapy or other treatment.  Severe events ar
 e usually incapacitating. 
 Grade 4 (Potentially Life threatening) :  Events causing inability to perform basic self-care 
functions OR Medical or operative intervention indicated to prevent permanent impairment, 
persistent disability, or death. 
 Grade 5 (Death)  
 
Version 3.0  35 
7/11/2017 10.4 Causality Assessment 
Causality (likelihood that the event is related to the study agent) will  be assessed from the 
time study dosing begins until 30 days following th e last dose consideri ng the factors listed 
under the following categories:  
 Definitely Related    
 reasonable temporal relationship 
 follows a known response pattern 
 clear evidence to suggest a causal relationship 
 there is no alternative etiology 
 
Probably Related  
 reasonable temporal relationship 
 follows a suspected response pattern (based on similar agents) 
 no evidence of a more likely alternative etiology 
 
Possibly Related  
 reasonable temporal relationship 
 little evidence for a more likely alternative etiology 
 
Unlikely Related  
 does not have a reasonable temporal relationship  
OR 
 good evidence for a more lik ely alternative etiology 
 
Not Related  
 does not have a temporal relationship          
OR 
 definitely due to an alternative etiology 
 
Note:  Other factors (e.g., dechallenge, rech allenge) should also be considered for each 
causality category when appropriate. Causality assessment is based on available information 
at the time of the assessment of the AE. The Investigator may revise the causality assessment 
as additional information becomes available. 
10.5 Reporting Procedures: Prospective Arm 
10.5.1 Adverse Events 
Throughout the study, the investigator must record all grade 3 or highe r events based on the “Division 
Of AIDS Table For Grading The Severity Of Adult And Pediatric Adverse Events” (Version 2.0, 
November 2014), not present at base line, on the appropriate Adverse Ev ent Form within 5 business days 
of identification of the event. If an event is present at baseline, is clearly  documented, and does not 
change in severity throughout th e study, it does not need to be captured on an Adverse Event Form. 
However, if the event resolves, or begins to resolv e, and then worsens again to a grade 3 or higher, it 
must be captured on an Adverse Event Form.  
 
 
Version 3.0  36 
7/11/2017 Within 5 business days of recogni tion of an adverse event, the Study Coordinator or site investigator 
will: 
 Complete an Adverse Event Form in the RedCap Database. 
 Record information on the adverse event in the participant’s medical chart. 
 Provide follow-up information when it becomes available 
 
10.5.2 Serious Adverse Events 
Deaths and immediately life threat ening SAEs must be reported in  the Redcap Database within 1 
business day after the site becomes aware of the event. All other SA Es must be reported within 3 
business days of site awareness.   
  
10.5.3 AE and SAE Recording/Documentation/Follow-up 
Adverse events will be collected from the time tr eatment starts on Day 0 through the end of the study 
follow-up period. Serious Adverse Even ts will be collected during th e treatment phase plus 30 days. 
At each contact with the subject as outlined abov e, information regarding AEs will be elicited by 
appropriate questioning and examinations and will be immediately recorded  on a source document. 
Source documents will include: progress notes, laborat ory reports, consult notes, phone call summaries, 
survey tools and data collection tools. Source documents will be re viewed in a timely manner by the 
research team. The onset date, the end date, the severi ty of each reportable event,  and the Investigator’s 
judgment of the AEs relationship to  SOF/LDV will also be recorded. 
Adverse events will be followed at a minimum until resolution of the AE or a return to baseline 
laboratory value. SAEs that occur after the study fo llow-up period that are repor ted to and are assessed 
by the Investigator to be possibly, probably, or definitely related must  be reported to the UCSF Project 
Manager and in the Redcap Da tabase, as described above. 
10.5.4 Adverse Events and Serious Adverse Events Exempt from Reporting 
Elective hospitalizati ons or hospital admissions for the purpo se of conduct of protocol mandated 
procedures are not to be reported as an SAE unless hospitalization is  prolonged due to complications. 
10.6 Reporting Procedures: Retrospective Arm 
Adverse event and safety monitoring is not required for the retrospective arm since the retrospective arm 
only involves data collection and elastography for those who consent. Elastography is ultrasound based and is without adverse events.  However, sites will be asked to record data on historical adverse events identified in the medical record for data analysis  (hospitalizations during treatment with DAA therapy, 
anemia requiring transfusion or EPO during treatment with DAA therapy, and death) but the 
retrospective arm participants are ex empt from ongoing safe ty monitoring.  
 
Version 3.0  37 
7/11/2017 11 SCHEDULE  OF EVENTS 
11.1 Schedule of Events Prospective Arm 
 Screening Day 0 Week 4 Week 12* Week 24* Day of Transplant 3M post treatment 6 M post treatment 
   
  Month 1 Month 3 Month 6 if treated 
for 24 weeks If transplant occurs 
post treatment with 
study drug 3 Months post 
treatmen t 6 Months or greater 
post treatment 
History and Physical X X X X X    X 
Vital signs and Weigh t  X X X X  X X 
Heigh t X             
Urinalysis   X            
Pregnancy Test: Urine   X1            
HBsAg X        
Anti-HBc X        
Virology Panel: (Historical only)               
         
           Anti-HIV Ab X              
           Anti-HCV Ab X              
           HCV Genotype X              
Plasma HCV RNA Levels   X X X X  X X 
CD4+ T-cell coun t  X2  X2 X2  X2 X2 
HIV-1 RNA (bDNA or PCR)  X2  X2 X2  X2 X2 
Standard of care liver staging X     X3 X      
SERUM CHEMISTRY         
Alanine aminotransferase (ALT)  X X X X  X X 
Albumin  X   X X    X 
Alkaline phosphatase  X X X X  X X 
Aspartate aminotransferase (AST)  X X X X  X X 
Bicarbonate  (If on ARV regimen containing 
tenofovir)  
X X X X  
X X 
Bilirubin, total, direc t  X X X X  X X 
Glucose  (repeat during treatment, but only if 
abnormal at baseline)  
X X  X  X   
    
Phosphate (If on ARV regimen containing tenofovir)  
X X X X  
X X 
Potassium (If on ARV regimen containing tenofovir)  
X X X X  
X X 
Sodium  X X X X  X X 
Serum Creatinine   X X X X  X X 
HEMATOLOGY         
Hemoglobin  X  X X    
Platelet Coun t  X  X X    
White Blood Cell (WBC) Coun t  X  X X    
Differential  X  X X    
    Neutrophils  X  X X    
    Lymphocytes  X  X X    
INR  X  X X    
RESEARCH         
 
Version 3.0  38 
7/11/2017  
    
*Subjects who are terminated early or who have  early treatment discontinuation should have an end of treatment visit as soon as possible after therapy is stopped. 
 
1 Urine pre gnanc y test for females with childbearin g potential must be ne gative on Da y 0 prior to dosin g with stud y agent 
2 documented historic results are acceptable. If not available, no t required unless considered standard of care, or may be run o n stored samples.  For HIV-1 RNA and CD4+ T-
cell counts, test results from primar y care provider should be obtained per standard of care (ever y 3 months) 
3only if treatment stops at week 12. Performed at screenin g and end of treatmen t 
4 Liver explant tissue collected and snap frozen or placed in RNA- later at the time of transplant, but onl y if sub ject achieved SVR pre-transplant.  
 
  Limited HCV Viral Kinetics  
X X   X X   
    
Liver explant tissue (if achieved SVR)          X4     
HLA X2              
Blood draw for immunologic studies  X X X X  X X 
Paxgene DNA (6.5 ml)   X            
Paxgene RNA (2.5 ml)   X X  X X  X   
IL28B rs12979860 (run off Paxgene DNA 
sample)  
X        
    
Blood for storage (8 cc SST serum, 6 cc EDTA)  X X X X  X X 
 
Version 3.0  39 
7/11/2017 11.2 Schedule of Events Retrospective Arm ( W a i v e r  o f  C o n s e n t )           
   
 
 
11.3  Schedule of Events Retrospective Arm: One Prospective Visit   
 
11.4   Screening Day 0 Week 4 Week 12* Week 24* 3M post treatment 6 M post treatment 
   
  Month 1 Month 3 Month 6 if treated 
for 24 weeks 3 Months post 
treatmen t 6 Months or greater 
post treatment 
Record Vital signs and Weigh t  X X X X X X 
Record Heigh t X            
Record Urinalysis   X           
Record  Virology Panel: (Historical only)              
           HBsAg X             
           Anti-HIV Ab X             
           Anti-HCV Ab X             
           HCV Genotype X             
Record  Plasma HCV RNA Levels   X X X X X X 
Record  CD4+ T-cell coun t  X  X X X X 
Record  HIV-1 RNA (bDNA or PCR)  X  X X X X 
Record  Standard of care liver staging X     X X     
SERUM CHEMISTRY        
Record  Alanine aminotransferase (ALT)  X X X X X X 
Record  Albumin  X   X X   X 
Record  Alkaline phosphatase  X X X X X X 
Record  Aspartate aminotransferase (AST)  X X X X X X 
Record  Bicarbonate  (If on ARV regimen 
containing tenofovir)  
X X X X X X 
Record  Bilirubin, total, direct  X X X X X X 
Record  Sodium  X X X X X X 
Record  Serum Creatinine   X X X X X X 
HEMATOLOGY        
Record  Hemoglobin  X  X X   
Record  Platelet Coun t  X  X X   
Record  White Blood Cell (WBC) Coun t  X  X X   
Record  Differential  X  X X   
    Record  Neutrophils  X  X X   
Record     Lymphocytes  X  X X   
Record  INR  X  X X    
RESEARCH Screening Day 0 
Informed Consent X  
Return to site for liver staging  by Fibroscan. 
Historical liver staging by Fibroscan or liver biopsy within the previous 12 months for standard 
of care is acceptable.  
X 
 
Version 3.0  40 
7/11/2017 12 MECHANISTIC  STUDIES:  PROSPECTIVE  ARM 
 
Viral Kinetics  Samples from  Days 0, week 4, and end of treatment (E OT) will be used to assess HCV viral load levels. 
 HCV Virologic Studies Full length HCV genome pyro seque ncing may be performed using the protocol as described and 
compared for variability of sequences [45].  rs12979860 (IL28B) Genetic Variant IL28B genetic variants have been shown to predict HCV treatment induced cl earance. The IL28B assay 
is a real-time PCR assay that util izes 5-prime nuclease activity of a thermostable polymerase and unique 
primers and SNP-specific probes to determine the genotype. Test results w ill not be used as inclusion or 
exclusion criteria, or to randomiz e subjects into tr eatment groups. 
 Immune Responses to HCV and HIV Both humoral and cellular immunity against HC V and HIV will be estimated before and during 
treatment to assess the effect of  HCV treatment on host immune re sponse against HCV. We may also 
perform multiplex PCR assays to dete ct ISGs before and during treatment. 
 HCV Genotypic and Phenotypic Resistance Monitoring Serum samples for genotypi c and phenotypic monitoring will be collected  
 Resistance monitoring will be completed in all subj ects who received study drug and were virologic 
failures as defined.  
 
Subjects who are determined by sequencing and phenot ypic analysis to have ha d mutations leading to 
SOF resistance will be requested to return at 12 week intervals for up to 48 weeks after the last dose of 
study drug to determine the time for the resist ant virus to return to background levels.  
 RNA Extraction from liver tissue In addition, this protocol will also allow for explorat ion of the potential of an HCV viral reservoir after 
achieving the primary endpoint of SVR12.   Subjects who receive treatment pre- transplant and achieve 
SVR, but who nonetheless progress to liver transpla ntation, will have a portion of the explanted liver 
snap frozen or placed in RNA- later .  Subsequently, liver RNA will be extracted and an attempt will be 
made to amplify residual HCV RN A using a protocol adapted from 
(http://www.ncbi.nlm.nih.gov/pubmed/22729600) that is sensitive to 2 copies of HCV RNA/ug of total liver RNA. If RNA is able to be amplified, th e relevant sequences of the HCV genome will be 
determined as above.  The ability to  obtain sufficient quantit ies of liver RNA for this analysis, given that 
the whole organ is explanted at tran splant, is a unique opportu nity to explore the pos sibility of residual 
HCV RNA after SVR in this cohort.   
 
Version 3.0  41 
7/11/2017 13 HAZARDS/DISCOMFORTS/RISKS:  PROSPECTIVE  ARM 
13.1 Drugs  
The combination of SOF/LDV is well tolerated with minimal adverse events. The safety profile of SOF 
includes approximately 1600 chronic HCV-infected subjects that have  been administered over 12 weeks 
of SOF in combination with a DAA, PEG-IFN, and/or RBV. No clinical  safety issues related to SOF 
have been identified to date. The safety profile of LDV include s over 1000 chronic HCV-infected 
subjects, of whom over 700 have been administered more than 12 weeks of LDV, which was given in 
combination with other DAAs, PEG-IFN, and/or RBV. No  clinical safety issues  related to LDV have 
been identified to date.  Furthermore, there is no expect ation of significant overlapping or new, unexpected toxicities upon 
administration of SOF/LDV together as an FDC.  To date, the SOF/LDV FDC ± RBV has been  
administered to over 500 HCV infected subjects in ongoing phase 2/3 trials, with over 200 subjects 
having received SOF/LDV FDC ± RBV for 12 weeks or more.  
 
Risk of bradycardia : People taking beta blockers, or who have an underlying cardiac condition or 
advanced liver disease, may be at  increased risk for br adycardia when taking Harvoni or Sovaldi with 
amiodarone.  
 Risk of Reduced Therapeutic Effect  of Harvoni Due to P-gp Inducers : Rifampin and St. John’s wort are 
not recommended for use w ith Harvoni as they may significantly decrease ledipasvir and sofosbuvir 
plasma concentrations.   
Related Products Not Recommended : Harvoni is not recommended for use with other products 
containing sofosbuvir (Sovaldi). 
 
Adverse Reactions  
Most common ( ≥10%, all grades) advers e reactions were fa tigue and headache. 
  Resistance  
An additional possible risk is the development of  class resistance to NS5B  inhibitors and NS5A 
inhibitors. Development of such re sistance could affect future therap eutic options. However all efforts 
will be made to manage the development of class specifi c mutations that could lead to cross resistance to 
other NS5B and NS5A inhibitors.  
13.2  Procedures 
13.2.1 Phlebotomy 
The primary risks of phlebotomy include  occasional bleeding or  bruising of the skin at  the site of needle 
puncture, and the sensation of transi ent lightheadedness or rarely, fainting and infection. The amount of 
blood drawn will be within the limits allowed for adu lt subjects by the NIH CC. 
  
 
Version 3.0  42 
7/11/2017 14 HUMAN  SUBJECT  PROTECTIONS 
Participants will be fully counseled prior to entry in to the study as to the potential risks of the study. 
Participants who, in the opinion of the study team, do not fully compre hend these potential risks will not 
be offered participation in the study. Participants will be monitored cl osely during their participation in 
the study.  
 
14.1 Gender, Ethnicity, and Race Considerations 
Participants will not be excluded based on gender, ethnicity or race.  
14.2  Children and Pregnant Women 
This study will be limited to adults 18 aged years or ol der. Insufficient data are available to evaluate the 
safety and efficacy of SOF/LDV FD C in the pediatric population. No ad equate human data are available 
to establish whether or not SOF/LDV FDC poses a ri sk to pregnancy outcomes.  In animal reproduction 
studies, no evidence of adverse deve lopmental outcomes was observed with SOF or LDV at exposures 
greater than those in humans at the recommende d human dose. Any woman of child-bear ing potential 
must have a negative urine pregnanc y test on the first day of treatment  (Visit 2/Day0) prior to receiving 
the first dose of FDC.   
14.3   HIV Testing   
Candidates without confirmed HIV infections will have HIV testing at screening. If HIV negative, they will be excluded from enrollment as this st udy is designed for HIV positive participants. 
  15 BENEFITS/COMPENSATION/ALTERNATIVES 
15.1   Benefits 
Participants may have the benefit of suppression or eradic ation of hepatitis C virus. Study medications 
will be provided free of charge  to all participants.   
 There may be no benefits to participating in this study.  
15.2 Alternatives 
Participants can receive approved he patitis C treatment with all oral interferon-free regimen as provided 
by their insurance and ordere d through their private physic ian or decide not to be treated at this time.   
  16 DATA
 SAFETY  AND  MONITORING 
An internal Operations and Safety Committee will meet monthly via teleconf erence to review ongoing 
study progress, to address ongoing oper ational issues that arise during the conduct of the trial, and to 
monitor accumulating data a ffecting subject safety.  
 
 
Version 3.0  43 
7/11/2017 Monthly teleconferences: The Oper ations and Safety Committee will review accrual, adverse event 
summary reports, HCV viral load measurements and treatment re sponse data, and data quality. 
 
Daily: The Operations and Safety Committee will be notified daily of any une xpected serious adverse 
events. Upon recognition of any safety concerns, a teleconference may be held  with the Operations 
Committee to discuss the concern.    The Operations Committee will cons ist of the following personnel: 
 Study Personnel: 
 Peter Stock (PI, UCSF) 
 Henry Masur 
 Beverly Alston-Smith 
 Shyam Kotilil 
 Theo Heller 
 Marion Peters 
 Norah Terrault 
 Eleanor Wilson 
 Rodney Rogers 
16.1 Specific Criteria to Pause Enrollment for Virologic/Therapeutic Failure and for 
Resistance 
16.1.1   Virologic/Therapeutic Failure Criteria to Pause Enrollment 
 Criteria 1: 5 of the first 20 participants experi ence treatment failure while receiving treatment   
16.2  If Criteria to Pause Enrollment are Met 
If criteria 1 is met, the viral kine tic, pharmacokinetic and resistance da ta will be reviewed with the study 
team and sponsor, and a decision wi ll be made as to whether to continue further enrollment.  
 Participants receiving study drugs at this time wi ll continue receiving treatment and follow-up visits 
through Week 52.     17 STUDY
 SITE  MONITORING 
The study will be conducted in compliance with  this protocol, International Conference on 
Harmonization (ICH) Guideline for Good Clinical Practices (GCP), and any applicable regulatory 
requirement(s). The investigator (and/or designee) will make study documents (e.g., consent forms, data 
pulls) and pertinent hospital or c linical records readily available for inspection by the local IRB and 
monitors under contract to NIAID/DAIDS.  As per ICH-GCP 5.18 and 21 CFR 312.50, “cl inical protocols are required to be adequately monitored 
by the study sponsor.” Monitors under contract to NIAI D/will visit the c linical research site to monitor 
all aspects of the study in accordance with the appr opriate regulations and the approved protocol. The 
 
Version 3.0  44 
7/11/2017 objectives of a monitoring visit will be: 1) to verify the existence of signed informed consent documents 
and documentation of the ICF process for each monitore d subject; 2) to verify the prompt and accurate 
recording of all monitore d data points, and prompt reporting of all SAEs; 3) to compare abstracted 
information (including CRIMSON data  abstracts) with individual participants’ records and source 
documents (participants’ charts, la boratory analyses and test result s, physicians’ progress notes, nurses’ 
notes, and any other relevant original subject information); and 4) to help  ensure investigators’ 
compliance with the protocol.  The m onitors also will inspect the clinical site regulatory files to ensure 
that regulatory requirements  a nd applicable guidelines (ICH-GCP) are being followed. During the 
monitoring visits, the inve stigator (and/or designee)  and other study personnel will be available to 
discuss the study progress and monitoring visit.  
 
A specific protocol monitoring plan will be discusse d with the Principal Investigator and study staff 
prior to enrollment. The plan will outline the frequency of monitoring visits based on such factors as 
study enrollment, data collection st atus and regulatory obligations. 
 
 
18 STORED  SAMPLES  AND  FUTURE  RESEARCH:  PROSPECTIVE  ARM 
Extra blood and tissue samples will be stored using a code name that  only the study team can link back 
to the participants. These samples will be stored for future research. Other i nvestigators may want to 
pursue additional research using thes e stored samples. If so, the study team will seek IRB approval prior 
to sharing of any samples.  Afte r approval, the study team may send th ese samples to th em, along with 
the coded label. Investigators wi ll use stored samples only for rese arch. At the completion of the 
protocol, samples and data will eith er be destroyed, or after IRB approva l, will be transferred to another 
existing protocol. The IRB will be notified in writing of any loss or destruction of stored samples.  
 
18.1 Research Use of Stored Human Specimens and Data 
Samples and data collected under th is protocol may be used to st udy mechanisms involved in the 
hepatitis C treatment response among participants.  Genetic  testing will be performed. 
  Access to research samples will be limited using a locked freezer. Samples and data will be stored using 
codes assigned by the investigators’  designees. Data will be kept in  a password-protected computer. 
Only investigators and their designees will have access to the samples and data. Samples will be stored 
and tracked utilizing the NCI FCRF Repository ope rated by Leidos Biomedic al Research Inc.   
 In the future, other investigators (both at NIH and outside) may wish to study these samples and/or data. 
In that case, IRB approval must be sought prior to any sharing of samples. Any clinical information 
shared about the sample with or without patient identifiers would si milarly require prior IRB approval. 
The research use of stored, unlinked or unidentif ied samples may be exem pt from the need for 
prospective IRB review and approval. Exemption requests will be submitted in writing to the NIH 
Office of Human Subjects Research, which is author ized to determine whether a research activity is 
exempt.    
 
Version 3.0  45 
7/11/2017 The NIH Intramural Protocol Deviati on definition related loss of or destruction of samples (for example, 
due to freezer malfunction) will be followed in re porting to the IRB: The deviation compromises the 
scientific integrity of the data collected for the study. 
 Any loss or unanticipated destructio n of >25% samples (for example, du e to freezer malfunction) or data 
(for example, misplacing a printout of data wi th identifiers) will be  reported to the IRB. 
 Additionally, participants may decide at any point not to have their samples stored. This will be treated as a withdrawal of the consent and in this case, the principal investigator will request destruction of all 
known remaining samples and report what was done to both the subjec t and to the IRB. This decision 
will affect the subject’s participation in this protocol but may not affect participations in any other protocols.  19 DATA
 MANAGEMENT  PLAN 
All research data and results will be collected centrally at UCSF using a Redcap data system. The 
Redcap data will be stored in a professionally managed, secure, web based, collaborative environment which can be made available to co-investigat ors if needed for analysis and review.  
   The site Principal Investigator wi ll be responsible for assuring that the clinical  data collected is 
complete, accurate, and recorded in a timely mann er.  Source documentation (the point of initial 
recording of information) s hould support the data collected , and must be signed and dated by the person 
recording and/or reviewing the da ta.  Source documents include all recordings of observations or 
notations of clinical activities , and all reports and records ne cessary for the evaluation and 
reconstruction of the clinical tria l.  Source documents include, but are not limited to, the subject’s 
medical records, laboratory reports, biopsy report s, progress notes, pharmacy records, and any other 
similar reports or r ecords of procedures performed during th e subject’s particip ation in the study. 
 All exploratory mechanistic data and stored sample s will be recorded and maintained using only the 
subject’s code for identification purposes, and will be  maintained by the NIH Intramural investigators.  
 All research data will be made available to scie ntific collaborators and supervisors for immediate 
review, consistent with requireme nts of confidentialit y. All research data, including the primary 
experimental results, will be reta ined for a minimum of 5 years to allow for analysis  and repetition by 
others of published material re sulting from the data.  Data mana gement, including the decision to 
publish, will be the responsibility of the PI. After public ation, all research data that  form the basis of that 
communication will be made available promptly and completely to  all responsible scientists seeking 
further information. Exceptions incl ude those requests that would infrin ge on confidentiality of clinical 
data or if unique materials we re obtained under agreements that preclude their dissemination. 
 20 STUDY
 RECORDS  RETENTION 
The investigator is responsible fo r retaining all essential documents  listed in the ICH Good Clinical 
Practice Guideline.  All essential documentation for all study subjec ts is to be maintained by the 
investigators in a secure storage facility for a minimum of three years per NIAID policies.  These 
 
Version 3.0  46 
7/11/2017 records are also to be maintain ed in compliance with IRB/EC, st ate, and federal medical records 
retention requirements, whichever is longest. All stored records are to be  kept confidential to the extent 
required by federal, state, and local law.  
 Should the investigator wish to as sign the study records to another pa rty and/or move them to another 
location, the investigator must provid e written notification of such intent to NIAID with the name of the 
person who will accept responsibility for the transferred records and/or  their new location. NIAID must 
be notified in writing and wr itten NIAID permission must be received by the site prior to destruction or 
relocation of research records.  21 ANONYMITY
 AND  CONFIDENTIALITY 
As each volunteer provides consent and is then enroll ed, he or she will be allocated a unique study 
number. To ensure subject confidentiality, these nume ric codes will substitute for personal identifiers on 
non-clinical research results and stored samples. The information obtained during the conduct of this 
clinical study is confidential, and disclosure to th ird parties other than thos e noted is prohibited. The 
results of the research study may be published, but par ticipants’ names or identities will not be revealed. 
Records will remain confidential. To maintain conf identiality, the PI will keep records in locked 
cabinets and the results of tests will be coded to prev ent association with subject  names. It is expected 
that this data will be reported in scientific jo urnals and scientific meetings. Confidentiality of 
participants will be maintained in all forms of reporting. Participants will be informed in general terms 
of the results as soon as practical.   22 PROTOCOL
 REGISTRATION 
 Prior to implementation of this protocol, and any subsequent full version amendments, each site must 
have the protocol and th e protocol consent form approved, as a ppropriate, by their local institutional 
review board (IRB)/ethics committee (EC) and a ny other applicable regul atory entity (RE). Upon 
receiving final approval, sites will submit all requir ed protocol registration documents to the DAIDS 
Protocol Registration Of fice (DAIDS PRO) at the Regulatory Support Center (RSC).  The DAIDS 
PRO will review the submitted protocol registration pack et to ensure that all of the required documents 
have been received.       Site-specific informed consent forms (ICFs) WILL  be reviewed and approved by the DAIDS PRO and 
sites will receive an Initial Regi stration Notification from the DAIDS PRO that indicates successful 
completion of the protocol registra tion process. A copy of the Initia l Registration Notification should 
be retained in the site's regulatory files.  Upon receiving final IRB/EC and any other applicable RE approval(s) for an amendment, sites should implement the amendment immediately.  Sites ar e required to submit an amendment registration 
packet to the DAIDS PRO at the RSC.  The DAIDS PRO will review the submitted protocol registration packet to ensure that all the required documents have been received. Site-specific ICF(s) 
WILL NOT be reviewed and approved by the DAIDS  PRO and sites will receive an Amendment 
Registration Notification when the DAIDS PRO receive s a complete registration packet. A copy of the 
Amendment Registration Notificat ion should be retained in th e site's regulatory files. 
 
 
Version 3.0  47 
7/11/2017 For additional information on the protocol registration process and specific documents required for 
initial and amendment registrations, refer to the cu rrent version of the DAIDS Protocol Registration 
Manual. 
  23 CONSENT
 PROCEDURES 
No screening procedures or tests for this study will be done before the consent process is completed.  
The protocol will be discussed verbally between the participant and one of the investigators or their 
designee during the screening visit. The participan t will be given ample opportunity to discuss any 
questions. The patient will then be given the consent document to read. After the participant has read this information, there will be further opportunity for discussion with one of the investigators. If 
protocol enrollment is then agreeable, the particip ant will sign the standard consent document and be 
given a copy of the signed document.  After the standard consent is signed, screening for study eligibility will commence.   
REFERENCES 
 1. de Vera, M.E., et al., Survival of liver transplant patient s coinfected with HIV and HCV is 
adversely impacted by recurrent hepatitis C.  Am J Transplant, 2006. 6(12): p. 2983-93. 
2. Duclos-Vallee, J.C., et al., Survival and recurrence of  hepatitis C after liver transplantation in 
patients coinfected with human immunode ficiency virus and hepatitis C virus.  Hepatology, 2008. 
47(2): p. 407-17. 
3. Mindikoglu, A.L., A. Regev, and L.S. Magder, Impact of human immunodeficiency virus on 
survival after liver transplant ation: analysis of United Netw ork for Organ Sharing database.  
Transplantation, 2008. 85(3): p. 359-68. 
4. Vennarecci, G., et al., Liver transplantation in HIV-positive patients.  Transplant Proc, 2007. 
39(6): p. 1936-8. 
5. Terrault, N.A., et al., Outcomes of liver transplant reci pients with hepatitis C and human 
immunodeficiency virus coinfection.  Liver Transpl, 2012. 18(6): p. 716-726. 
6. Miro, J.M., et al., Outcome of HCV/HIV-coinfected liver tr ansplant recipients: a prospective and 
multicenter cohort study. Am J Transplant, 2012. 12(7): p. 1866-76. 
7. Gane, E.J., et al., Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.  N 
Engl J Med, 2013. 368(1): p. 34-44. 
8. Lawitz, E. and E.J. Gane, Sofosbuvir for previously untreated  chronic hepatitis C infection.  N 
Engl J Med, 2013. 369(7): p. 678-9. 
9. Osinusi, A., et al., Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with 
unfavorable treatment ch aracteristics: a random ized clinical trial. JAMA, 2013. 310(8): p. 804-
11. 
10. Curry, M. and e. al, Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV 
Infection after Liver Transplantation.  Program and abstracts of th e 64th Annual Meeting of the 
American Association for the Study of Liver Diseases; N ovember 1-5, 2013; Washington, DC, 
2013. AASLD 2013, abstract LB-2. 
11. Charlton, M. and e. al, Sofosbuvir and Ribavirin for the Treatment of Established Recurrent 
Hepatitis C Infection After Liver Transplantat ion: Preliminary Result s of a Prospective, 
Multicenter Study.  Program and abstracts of the 64th  Annual Meeting of the American 
 
Version 3.0  48 
7/11/2017 Association for the Study of Liver Diseas es; November 1-5, 2013; Washington, DC, 2013. 
AASLD 2013, abstract LB-2. 
12. Gane, E., C. Stedman, and R. Hyland, All-oral sofosbuvir-based 12-week regimens for the 
treatment of chronic HCV infe ction: the ELECTRON study. .  48th Annual Meeting of the 
European Association for the Study of the Liver (EASL 2013).  Amsterdam. April 24-28, 2013, 
2013. EASL 2013, Abstract 14. 
13. Lawitz, E. and e. al., Once daily sofosbuvir/ledipasvir fixed dose combination with or without 
ribavirin resulted in ≥95% sustained virologic response in patients with HCV genotype 1, 
including patients with cirrhosis: the LONESTAR trial. .  Program and abstracts of the 64th 
Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC, 2013. AASLD 2013, abstract 215. 
14. Gane, E.J., et al., Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A 
Inhibitor Ledipasvir or the NS5B Non-Nucleo side Inhibitor GS-9669 Against HCV Genotype 1 
Infection.  Gastroenterology, 2013. 
15. Lawitz, E., et al., Sofosbuvir and ledipasvir fi xed-dose combination with and without ribavirin in 
treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection 
(LONESTAR): an open-label,  randomised, phase 2 trial.  Lancet, 2014. 383(9916): p. 515-23. 
16. Armstrong, G.L., et al., The prevalence of hepatitis C virus infection in the United States, 1999 
through 2002. Ann Intern Med, 2006. 144(10): p. 705-14. 
17. Kim, W.R., The burden of hepatitis C in the United States.  Hepatology, 2002. 36(5 Suppl 1): p. 
S30-4. 
18. Kim, W.R., et al., Burden of liver disease in the Un ited States: summary of a workshop.  
Hepatology, 2002. 36(1): p. 227-42. 
19. Kohli, A., et al., Combination oral, ribavirin free, antiv iral therapy to optimize treatment 
outcomes for hepatitis C GT-1 treatment naive patients: interim results from the NIAID 
SYNERGY Trial.  Program and abstracts of the 64th Annual Meeting of the American Association 
for the Study of Liver Diseases; November 1-5, 2013; Washington, DC, 2013. AASLD 2013, 
Abstract LB-8. 
20. Sherman, K.E., et al., Hepatitis C Virus prevalence among patients infected with Human 
Immunodeficiency Virus: a cross-sectional analysi s of the US adult AIDS Clinical Trials Group.  
Clin Infect Dis, 2002. 34(6): p. 831-7. 
21. Rosenthal, E., et al., Liver-related mortality in human-immunodeficiency- virus-infected patients 
between 1995 and 2003 in the French GERMIV IC Joint Study Group Network (MORTAVIC 
2003 Study).  J Viral Hepat, 2007. 14(3): p. 183-8. 
22. Ly, K.N., et al., The increasing burden of mortality from  viral hepatitis in the United States 
between 1999 and 2007. Ann Intern Med, 2012. 156(4): p. 271-8. 
23. Eyster, M.E., et al., Natu 
ral history of hepatitis C virus infection in multitransfused 
hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter 
Hemophilia Cohort Study.  J Acquir Immune Defic Syndr, 1993. 6(6): p. 602-10. 
24. Lesens, O., et al., Hepatitis C virus is related to progressive liver disease in human 
immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic 
infection.  J Infect Dis, 1999. 179(5): p. 1254-8. 
25. Weber, R., et al., Liver-related deaths in persons in fected with the human immunodeficiency 
virus: the D:A:D study. Arch Intern Med, 2006. 166(15): p. 1632-41. 
26. Soriano, V., et al., Challenges and opportunities for hepati tis C drug development in HIV-HCV 
coinfected patients.  AIDS, 2011. 
 
Version 3.0  49 
7/11/2017 27. Sulkowski, M.S., Hepatitis C Virus Infection in HIV-infected Patients.  Curr Infect Dis Rep, 
2001. 3(5): p. 469-476. 
28. Benhamou, Y., et al., Factors affecting liver fibrosis in human immunodeficiency virus-and 
hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.  Hepatology, 2001. 
34(2): p. 283-7. 
29. Rai, R., et al., Severity and correlates of liver disease in hepatitis C virus-infected injection drug 
users. Hepatology, 2002. 35(5): p. 1247-55. 
30. Thein, H.H., et al., Natural history of hepatitis C virus in fection in HIV-infe cted individuals and 
the impact of HIV in the era of highly ac tive antiretroviral therapy: a meta-analysis.  AIDS, 
2008. 22(15): p. 1979-91. 
31. Pineda, J.A., et al., HIV coinfection shortens the survival of patients with hepatitis C virus-
related decompensated cirrhosis.  Hepatology, 2005. 41(4): p. 779-89. 
32. Hernandez, M.D. and K.E. Sherman, HIV/hepatitis C coinfection natural history and disease 
progression.  Curr Opin HIV AIDS, 2011. 6(6): p. 478-82. 
33. Benhamou, Y., et al., Liver fibrosis progression in human immunodeficiency virus and hepatitis 
C virus coinfected patients. The Multivirc Group.  Hepatology, 1999. 30(4): p. 1054-8. 
34. Garcia-Samaniego, J., et al., Hepatocellular carcinoma in HIV-infected patients with chronic 
hepatitis C.  Am J Gastroenterol, 2001. 96(1): p. 179-83. 
35. Roland, M.E., et al., HIV-infected liver and kidney trans plant recipients: 1- and 3-year 
outcomes.  Am J Transplant, 2008. 8(2): p. 355-65. 
36. Ragni, M.V., et al., Pretransplant survival is shorter in HIV-positive than HIV-negative subjects 
with end-stage liver disease.  Liver Transpl, 2005. 11(11): p. 1425-30. 
37. Duclos-Vallee, J.C., B. Falissard, and D. Samuel, Liver transplant outcomes in HIV-infected 
patients: a systematic review and me ta-analysis with a synthetic cohort.  AIDS, 2011. 25(13): p. 
1675-6. 
38. Viale, P., U. Baccarani, and M. Tavio, Liver transplant in patients with HIV: infection risk 
associated with HIV and post- transplant immunosuppression.  Curr Infect Dis Rep, 2008. 10(1): 
p. 74-81. 
39. Sovaldi [package insert]. Foster City, CA. Gilead; 2017. 
40. Harvoni [package insert]. Foster City, CA. Gilead; 2017. 
41. Alter, H.J. and T.J. Liang, Hepatitis C: the end of the be ginning and possibly the beginning of 
the end.  Ann Intern Med, 2012. 156(4): p. 317-8. 
42. Thomas, D.L., Options for treatment of hepatiti s C in HIV-infected persons.  J Hepatol, 2006. 
44(1 Suppl): p. S40-3. 
43. Sidique, N., et al., HIV/HCV-coinfected natural viral suppr essors have better virologic responses 
to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.  J Acquir Immune Defic Syndr, 
2011. 58(2): p. e38-40. 
44. Afdhal, N., et al., Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.  N 
Engl J Med, 2014. 370(16): p. 1483-93. 
45. Liu, Z., et al., Accurate representation of the hepatit is C virus quasispecies in 5.2-kilobase 
amplicons.  J Clin Microbiol, 2004. 42(9): p. 4223-9. 
  